{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "aa94a0e5",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "import spacy\n",
    "from spacy import displacy\n",
    "import xmltodict\n",
    "from pathlib import Path\n",
    "import json\n",
    "from collections import defaultdict\n",
    "import jsbeautifier"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "65e41728",
   "metadata": {},
   "source": [
    "### The first part is for the NIO annotations: \n",
    "- visusalize the NIO annotations removing the nested annotations in disPlacy\n",
    "- output the full NIO annotations (including the nested ones) in the json format"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "5ae9e6fb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# automate the text span reading process\n",
    "## step 1: read the outputs from the PathogenExperimenter, the outputs look like:\n",
    "# ['article id:217583',\n",
    "#  'predicted mention id:[obo:GO_0007613, obo:OGMS_0000031, NDDUO:Study_type, NDDUO:Study_type, obo:NBO_0000175, obo:GO_0007613, obo:BFO_0000015, obo:NBO_0000215, obo:NBO_0000175, obo:GO_0007613, obo:OBI_0000753, obo:BFO_0000015, obo:NBO_0000175, obo:GO_0007613, obo:BFO_0000015, obo:NBO_0000175, obo:GO_0007613]',\n",
    "#  'predicted mention starts:[64, 382, 448, 448, 525, 546, 645, 725, 742, 763, 820, 1061, 1355, 1384, 1664, 1777, 1798]',\n",
    "#  'predicted mention ends:[70, 389, 453, 453, 541, 552, 655, 730, 758, 769, 825, 1071, 1371, 1390, 1674, 1793, 1804]',\n",
    "#  '----------',\n",
    "## update for step 1: after running the articles in a large volume ~ 1000, the outputs look like:\n",
    "# [[ISI_000328805100012], [[obo:GO_0007610, obo:NBO_0000313, ...]],\n",
    "#  [[8, 8, ...]], [[17, 17, ...]], \n",
    "#  [NLM_17085785], [[AlzheimerOntology:amyloid_beta_protein, AlzheimerOntology:amyloid_beta_protein, ...]],\n",
    "#  [[54, 54, ...]], [[66, 66, ...]], ...]\n",
    "# [[article_title 1], [[UIDs for a1]], [[starting indices for a1]], [[ending indices for a1]],\n",
    "#  [article_title 2], [[UIDs for a2]], [[starting indices for a2]], [[ending indices for a2]], ...]\n",
    "\n",
    "\n",
    "output_path = \"/Users/yidesdo21/Projects/outputs/10_ptc_ten_recent/txt/\"\n",
    "# output_file = \"02_nio_with_canonical_as_variant/02_07_memory_recent_10.txt\"\n",
    "output_file = \"nio_ten_recent_spans_nested_case.txt\"\n",
    "\n",
    "with open(output_path+output_file) as f:\n",
    "    output = f.read().splitlines()[14:-2]\n",
    "    \n",
    "\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "395ea6d4",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e10f8375",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "365f9778",
   "metadata": {},
   "outputs": [],
   "source": [
    "## step 2: link mention id to the canonical\n",
    "##  goal - turn the nio.xml into a dictionary format\n",
    "##  this is to use the canonical as the label in the spaCy's annotation \n",
    "## input format:\n",
    "# <?xml version=\"1.0\" ?>\n",
    "# <synonym>\n",
    "#     <token id=\"NDDO:NDDO_00000021\" canonical=\"visit\">\n",
    "#         <variant base=\"visit\"/>\n",
    "#     </token>\n",
    "#     <token id=\"NDDO:NDDO_00000022\" canonical=\"diagnostic data\">\n",
    "#         <variant base=\"diagnostic data\"/>\n",
    "#     </token>\n",
    "# </synonym>\n",
    "\n",
    "## expected format:\n",
    "# {\"NDDO:NDDO_00000021\": \"visit\",\n",
    "#  \"NDDO:NDDO_00000022\": \"diagnostic data\"}\n",
    "\n",
    "xml_path = \"/Users/yidesdo21/Projects/inputs/dictionary/nio_ado_case.xml\"\n",
    "# xml_path = \"/Users/yidesdo21/Projects/codes/nio_iri_v3_2.xml\"\n",
    "\n",
    "with open(xml_path) as f:\n",
    "    nio_xml = f.read()\n",
    "\n",
    "token_cano = dict()  # {\"token_id\": \"canonical\"}\n",
    "nio_dict = xmltodict.parse(nio_xml)\n",
    "\n",
    "canos = nio_dict[\"synonym\"][\"token\"]\n",
    "for cano in canos:\n",
    "    token_cano[cano[\"@id\"]] = cano[\"@canonical\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "717f7f44",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "568d4c93",
   "metadata": {},
   "outputs": [],
   "source": [
    "## step 3: pull out the mentioned entities by slicing the article with starting and ending indices\n",
    "##  3.1: create the package for each article, so we can access the mention ids, starting \n",
    "##       and ending indices for each article with the same index.\n",
    "article_ids = list() # article_ids[i] to access the article id\n",
    "mention_ids = list() # mention_ids[i] to access the list of mention ids for the [i]th article\n",
    "start_ind = list()   # start_ind[i] to access the list of start indices for the [i]th article\n",
    "end_ind = list()     # end_ind[i] to access the list of end indices for the [i]th article\n",
    "docs = list()   # to create the list of dictionaries as the input for spaCy visualizer\n",
    "                 # this has to be ourside of the articles iteration\n",
    "docs_text = list()   # not for diaplacy, but for showing the mentioned entites with the canonical  \n",
    "\n",
    "for k in range(len(output)):\n",
    "    if k%5 == 0:  \n",
    "        article_ids.append(output[k].split(\":\")[1])\n",
    "    elif k%5 == 1:\n",
    "        mention_id = output[k].split(\"[\")[1][:-1].split(\", \")\n",
    "        mention_ids.append(mention_id)\n",
    "    elif k%5 == 2:\n",
    "        starts = output[k].split(\"[\")[1][:-1].split(\", \")\n",
    "        start_ind.append([int(x) for x in starts])\n",
    "    elif k%5 == 3:\n",
    "        ends = output[k].split(\"[\")[1][:-1].split(\", \")\n",
    "        end_ind.append([int(x) for x in ends])    \n",
    "        \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c14eb7c5",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "ffe65ca7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'span': (0, 3), 'mention': 'Tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (20, 29), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (58, 62), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (81, 90), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (94, 113), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (94, 105), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (94, 103), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (106, 113), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (106, 113), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (114, 119), 'mention': 'brain', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (114, 119), 'mention': 'brain', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (151, 160), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (171, 194), 'mention': 'neurofibrillary tangles', 'identifier': 'AlzheimerOntology:neurofibrillary_tangle', 'concept': 'neurofibrillary tangle', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (187, 194), 'mention': 'tangles', 'identifier': 'AlzheimerOntology:Tangles', 'concept': 'Tangle', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (262, 281), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (262, 273), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (262, 271), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (274, 281), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (274, 281), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (283, 285), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (291, 296), 'mention': 'other', 'identifier': 'obo:IAO_0000230', 'concept': 'other', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (297, 308), 'mention': 'tauopathies', 'identifier': 'obo:ND_0000151', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (297, 308), 'mention': 'tauopathies', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (322, 325), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (468, 472), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (485, 488), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (571, 580), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (671, 680), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (733, 739), 'mention': 'brains', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (733, 739), 'mention': 'brains', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (770, 772), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (867, 879), 'mention': 'brain tissue', 'identifier': 'AlzheimerOntology:brain_tissue', 'concept': 'brain tissue', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (867, 872), 'mention': 'brain', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (867, 872), 'mention': 'brain', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (908, 913), 'mention': 'model', 'identifier': 'obo:NBO_0000215', 'concept': 'observational learning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (908, 913), 'mention': 'model', 'identifier': 'NDDUO:model', 'concept': 'model', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (925, 933), 'mention': 'studying', 'identifier': 'NDDUO:Study_type', 'concept': 'clinical trial study', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (934, 938), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (963, 972), 'mention': 'screening', 'identifier': 'NDDUO:Screening', 'concept': 'Screening', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (977, 987), 'mention': 'inhibitors', 'identifier': 'NDDUO:inhibitor', 'concept': 'inhibitor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (991, 994), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (995, 1006), 'mention': 'aggregation', 'identifier': 'NDDUO:Cluster', 'concept': 'Cluster', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (44, 56), 'mention': 'amyloid-beta', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (44, 51), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (228, 240), 'mention': 'amyloid-beta', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (228, 235), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1010, 1014), 'mention': 'like', 'identifier': 'obo:NBO_0000282', 'concept': 'liking', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1415, 1420), 'mention': 'assay', 'identifier': 'obo:OBI_0000070', 'concept': 'assay', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1694, 1701), 'mention': 'samples', 'identifier': 'NDDUO:Sampling', 'concept': 'Sampling', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1747, 1752), 'mention': 'assay', 'identifier': 'obo:OBI_0000070', 'concept': 'assay', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1804, 1808), 'mention': 'many', 'identifier': 'AlzheimerOntology:Memory_orientation_screening_test', 'concept': 'Memory Orientation Screening Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1809, 1816), 'mention': 'studies', 'identifier': 'NDDUO:Study_type', 'concept': 'clinical trial study', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1846, 1865), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1846, 1857), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1846, 1855), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1858, 1865), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1858, 1865), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1867, 1869), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1886, 1895), 'mention': 'treatment', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1886, 1895), 'mention': 'treatment', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (28, 37), 'mention': 'receptors', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (42, 51), 'mention': 'microglia', 'identifier': 'AlzheimerOntology:Microglia', 'concept': 'Microglia', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (110, 122), 'mention': 'amyloid-beta', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (110, 117), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (165, 173), 'mention': 'receptor', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (183, 194), 'mention': 'endocytosis', 'identifier': 'AlzheimerOntology:Endocytosis', 'concept': 'Endocytosis', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (204, 213), 'mention': 'microglia', 'identifier': 'AlzheimerOntology:Microglia', 'concept': 'Microglia', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (251, 256), 'mention': 'brain', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (251, 256), 'mention': 'brain', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (276, 296), 'mention': 'inflammatory cascade', 'identifier': 'AlzheimerOntology:inflammation', 'concept': 'inflammation', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (276, 288), 'mention': 'inflammatory', 'identifier': 'AlzheimerOntology:inflammation', 'concept': 'inflammation', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (371, 380), 'mention': 'receptors', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (393, 401), 'mention': 'membrane', 'identifier': 'AlzheimerOntology:Membrane', 'concept': 'Membrane', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (462, 471), 'mention': 'receptors', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (562, 571), 'mention': 'microglia', 'identifier': 'AlzheimerOntology:Microglia', 'concept': 'Microglia', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (718, 727), 'mention': 'membranes', 'identifier': 'AlzheimerOntology:Membrane', 'concept': 'Membrane', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (758, 767), 'mention': 'receptors', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (779, 788), 'mention': 'microglia', 'identifier': 'AlzheimerOntology:Microglia', 'concept': 'Microglia', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (894, 901), 'mention': 'process', 'identifier': 'obo:BFO_0000015', 'concept': 'process', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (894, 901), 'mention': 'process', 'identifier': 'span:Process', 'concept': 'process', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1187, 1193), 'mention': 'oxygen', 'identifier': 'AlzheimerOntology:oxygen', 'concept': 'oxygen', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1232, 1241), 'mention': 'receptors', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1327, 1338), 'mention': 'antioxidant', 'identifier': 'AlzheimerOntology:antioxidant', 'concept': 'antioxidant', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1382, 1394), 'mention': 'phagocytosis', 'identifier': 'AlzheimerOntology:phagocytosis', 'concept': 'phagocytosis', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1500, 1505), 'mention': 'study', 'identifier': 'NDDUO:Study_type', 'concept': 'clinical trial study', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1680, 1685), 'mention': 'other', 'identifier': 'obo:IAO_0000230', 'concept': 'other', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1686, 1693), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1686, 1693), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1694, 1706), 'mention': 'intervention', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1694, 1706), 'mention': 'intervention', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1723, 1731), 'mention': 'receptor', 'identifier': 'AlzheimerOntology:Receptors', 'concept': 'Receptor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (28, 32), 'mention': 'Drug', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (48, 67), 'mention': \"Alzheimer's Disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (48, 59), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (48, 57), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (60, 67), 'mention': 'Disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (60, 67), 'mention': 'Disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (199, 214), 'mention': 'clinical trials', 'identifier': 'NDDUO:Clinical_trial', 'concept': 'thing related to clinical trial', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (199, 207), 'mention': 'clinical', 'identifier': 'NDDUO:Clinical', 'concept': 'Clinical thing', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (219, 238), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (219, 230), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (219, 228), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (231, 238), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (231, 238), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (240, 242), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (314, 323), 'mention': 'treatment', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (314, 323), 'mention': 'treatment', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (349, 355), 'mention': 'groups', 'identifier': 'AlzheimerOntology:control_group_study_arm', 'concept': 'control group study arm', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (369, 378), 'mention': 'protocols', 'identifier': 'obo:OBI_0000272', 'concept': 'protocol', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (383, 399), 'mention': 'outcome measures', 'identifier': 'NDDUO:outcome_measure', 'concept': 'outcome measure', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (383, 390), 'mention': 'outcome', 'identifier': 'AlzheimerOntology:Outcome', 'concept': 'Outcome', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (383, 390), 'mention': 'outcome', 'identifier': 'NDDUO:Outcome', 'concept': 'Thing related to outcome', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (415, 424), 'mention': 'treatment', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (415, 424), 'mention': 'treatment', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (482, 490), 'mention': 'outcomes', 'identifier': 'AlzheimerOntology:Outcome', 'concept': 'Outcome', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (482, 490), 'mention': 'outcomes', 'identifier': 'NDDUO:Outcome', 'concept': 'Thing related to outcome', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (540, 547), 'mention': 'learned', 'identifier': 'obo:GO_0007612', 'concept': 'learning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (578, 589), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (578, 587), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (667, 672), 'mention': 'other', 'identifier': 'obo:IAO_0000230', 'concept': 'other', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (722, 730), 'mention': 'planning', 'identifier': 'obo:MF_0000027', 'concept': 'planning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (722, 730), 'mention': 'planning', 'identifier': 'obo:OBI_0000260', 'concept': 'plan', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (722, 730), 'mention': 'planning', 'identifier': 'obo:OBI_0000339', 'concept': 'planning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (731, 737), 'mention': 'stages', 'identifier': 'NDDUO:Stages', 'concept': 'thing related to stage', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (756, 770), 'mention': 'clinical trial', 'identifier': 'NDDUO:Clinical_trial', 'concept': 'thing related to clinical trial', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (756, 764), 'mention': 'clinical', 'identifier': 'NDDUO:Clinical', 'concept': 'Clinical thing', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (788, 790), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (899, 912), 'mention': 'interventions', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (899, 912), 'mention': 'interventions', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (989, 996), 'mention': 'cohorts', 'identifier': 'NDDO:NDDO_00000107', 'concept': 'cohort', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (989, 996), 'mention': 'cohorts', 'identifier': 'AlzheimerOntology:Cohort_effect', 'concept': 'Cohort effect', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1023, 1025), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1034, 1044), 'mention': 'population', 'identifier': 'AlzheimerOntology:Populations', 'concept': 'Population', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1046, 1048), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1049, 1054), 'mention': 'drugs', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1056, 1065), 'mention': 'treatment', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1056, 1065), 'mention': 'treatment', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1260, 1262), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1263, 1273), 'mention': 'treatments', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1263, 1273), 'mention': 'treatments', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (9, 13), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (9, 13), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (83, 102), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (83, 94), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (83, 92), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (95, 102), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (95, 102), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (162, 181), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (162, 173), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (162, 171), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (174, 181), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (174, 181), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (183, 185), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (227, 234), 'mention': 'neurons', 'identifier': 'NDDUO:Neurons', 'concept': 'Neuron', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (254, 260), 'mention': 'others', 'identifier': 'obo:IAO_0000230', 'concept': 'other', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (365, 372), 'mention': 'nucleus', 'identifier': 'AlzheimerOntology:Nucleus', 'concept': 'Nucleus', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (373, 376), 'mention': 'RNA', 'identifier': 'AlzheimerOntology:RNA', 'concept': 'RNA', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (408, 412), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (408, 412), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (514, 518), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (514, 518), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (557, 559), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (639, 646), 'mention': 'neurons', 'identifier': 'NDDUO:Neurons', 'concept': 'Neuron', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (654, 660), 'mention': 'brains', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (654, 660), 'mention': 'brains', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (674, 678), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (686, 690), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (686, 690), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (700, 704), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (732, 734), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (779, 783), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (779, 783), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (821, 825), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (821, 825), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (865, 878), 'mention': 'tau pathology', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (865, 868), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (944, 957), 'mention': 'tau pathology', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (944, 947), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (986, 993), 'mention': 'neurons', 'identifier': 'NDDUO:Neurons', 'concept': 'Neuron', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1001, 1006), 'mention': 'mouse', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1007, 1017), 'mention': 'hippocampi', 'identifier': 'obo:FMA_62493', 'concept': 'Hippocampus', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1007, 1017), 'mention': 'hippocampi', 'identifier': 'AlzheimerOntology:Hippocampus', 'concept': 'Hippocampus', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1042, 1045), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1099, 1103), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:APOE', 'concept': 'APOE', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1099, 1103), 'mention': 'ApoE', 'identifier': 'AlzheimerOntology:ApoE_Protein', 'concept': 'ApoE Protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1157, 1170), 'mention': 'tau pathology', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1157, 1160), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (0, 9), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (24, 27), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (24, 27), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (86, 105), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (86, 97), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (86, 95), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (98, 105), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (98, 105), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (143, 148), 'mention': 'other', 'identifier': 'obo:IAO_0000230', 'concept': 'other', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (149, 158), 'mention': 'mutations', 'identifier': 'AlzheimerOntology:mutation', 'concept': 'mutation', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (289, 295), 'mention': 'brains', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (289, 295), 'mention': 'brains', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (319, 323), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (359, 373), 'mention': 'cultured cells', 'identifier': 'AlzheimerOntology:Cell_cultures', 'concept': 'Cell culture', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (44, 56), 'mention': 'amyloid-beta', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (44, 51), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (116, 120), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (152, 177), 'mention': 'Amyloid precursor protein', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (152, 159), 'mention': 'Amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (170, 177), 'mention': 'protein', 'identifier': 'AlzheimerOntology:protein', 'concept': 'protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (179, 182), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (179, 182), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (202, 207), 'mention': 'model', 'identifier': 'obo:NBO_0000215', 'concept': 'observational learning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (202, 207), 'mention': 'model', 'identifier': 'NDDUO:model', 'concept': 'model', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (223, 235), 'mention': 'amyloid-beta', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (223, 230), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (252, 260), 'mention': 'function', 'identifier': 'obo:BFO_0000034', 'concept': 'function', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (252, 260), 'mention': 'function', 'identifier': 'snap:Function', 'concept': 'function', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (264, 283), 'mention': 'Alzheimer?s disease', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (264, 275), 'mention': 'Alzheimer?s', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (264, 273), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (276, 283), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (276, 283), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (285, 287), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (298, 308), 'mention': 'phenotypes', 'identifier': 'obo:OGMS_0000023', 'concept': 'phenotype', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (328, 332), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (373, 376), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (373, 376), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (464, 467), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (464, 467), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (595, 609), 'mention': 'amyloid plaque', 'identifier': 'AlzheimerOntology:presence_of_amyloid_plaque', 'concept': 'presence of amyloid plaque', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (595, 602), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (603, 609), 'mention': 'plaque', 'identifier': 'AlzheimerOntology:presence_of_amyloid_plaque', 'concept': 'presence of amyloid plaque', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (603, 609), 'mention': 'plaque', 'identifier': 'AlzheimerOntology:senile_plaque', 'concept': 'presence of senile plaque', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (626, 628), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (747, 755), 'mention': 'function', 'identifier': 'obo:BFO_0000034', 'concept': 'function', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (747, 755), 'mention': 'function', 'identifier': 'snap:Function', 'concept': 'function', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (830, 838), 'mention': 'function', 'identifier': 'obo:BFO_0000034', 'concept': 'function', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (830, 838), 'mention': 'function', 'identifier': 'snap:Function', 'concept': 'function', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (842, 846), 'mention': 'vivo', 'identifier': 'NDDUO:In_vivo', 'concept': 'In vivo thing', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (899, 903), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (947, 952), 'mention': 'brain', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (947, 952), 'mention': 'brain', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (971, 974), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (971, 974), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1002, 1006), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1045, 1052), 'mention': 'assayed', 'identifier': 'obo:OBI_0000070', 'concept': 'assay', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1276, 1280), 'mention': 'male', 'identifier': 'NDDUO:male', 'concept': 'male', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1285, 1291), 'mention': 'female', 'identifier': 'NDDUO:female', 'concept': 'female', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1292, 1296), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1428, 1432), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1464, 1467), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1464, 1467), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1472, 1484), 'mention': 'Presenilin 1', 'identifier': 'AlzheimerOntology:presenilin_1', 'concept': 'presenilin 1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1472, 1482), 'mention': 'Presenilin', 'identifier': 'AlzheimerOntology:presenilin', 'concept': 'presenilin', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1486, 1489), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1486, 1489), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1494, 1498), 'mention': 'mice', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1560, 1563), 'mention': 'APP', 'identifier': 'AlzheimerOntology:APP', 'concept': 'APP', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1560, 1563), 'mention': 'APP', 'identifier': 'AlzheimerOntology:amyloid_precursor_protein', 'concept': 'amyloid precursor protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1596, 1608), 'mention': 'mouse models', 'identifier': 'NDDUO:In_vivo_models', 'concept': 'In vivo model', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1596, 1601), 'mention': 'mouse', 'identifier': 'NDDUO:Mouse_', 'concept': 'Mouse', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1602, 1608), 'mention': 'models', 'identifier': 'obo:NBO_0000215', 'concept': 'observational learning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1602, 1608), 'mention': 'models', 'identifier': 'NDDUO:model', 'concept': 'model', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1612, 1614), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1798, 1809), 'mention': 'aggregation', 'identifier': 'NDDUO:Cluster', 'concept': 'Cluster', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1856, 1863), 'mention': 'role of', 'identifier': 'obo:RO_0000081', 'concept': 'role of', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1856, 1860), 'mention': 'role', 'identifier': 'obo:BFO_0000023', 'concept': 'role', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1856, 1860), 'mention': 'role', 'identifier': 'snap:Role', 'concept': 'role', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1910, 1917), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1910, 1917), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (4, 8), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (18, 37), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (18, 29), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (18, 27), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (30, 37), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (30, 37), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (38, 42), 'mention': 'risk', 'identifier': 'NDDUO:Risk_factor', 'concept': 'Risk factor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (87, 90), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (108, 125), 'mention': 'cognitive decline', 'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline', 'concept': 'Moderate cognitive Decline', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (108, 125), 'mention': 'cognitive decline', 'identifier': 'AlzheimerOntology:mental_disorder', 'concept': 'mental disorder', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (108, 117), 'mention': 'cognitive', 'identifier': 'AlzheimerOntology:Cognitive_Tests', 'concept': 'Cognitive Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (144, 148), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (212, 216), 'mention': 'risk', 'identifier': 'NDDUO:Risk_factor', 'concept': 'Risk factor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (227, 246), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (227, 238), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (227, 236), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (239, 246), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (239, 246), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (248, 250), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (268, 281), 'mention': 'tau pathology', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (268, 271), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (291, 294), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (332, 344), 'mention': 'amyloid beta', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (332, 339), 'mention': 'amyloid', 'identifier': 'AlzheimerOntology:amyloid_beta_protein', 'concept': 'amyloid beta protein', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (369, 373), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (406, 409), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (449, 456), 'mention': 'samples', 'identifier': 'NDDUO:Sampling', 'concept': 'Sampling', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (458, 501), 'mention': \"Alzheimer's Disease Neuroimaging Initiative\", 'identifier': 'AlzheimerOntology:neuroimaging', 'concept': 'neuroimaging', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (458, 477), 'mention': \"Alzheimer's Disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (458, 469), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (458, 467), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (470, 477), 'mention': 'Disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (470, 477), 'mention': 'Disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (478, 490), 'mention': 'Neuroimaging', 'identifier': 'AlzheimerOntology:neuroimaging', 'concept': 'neuroimaging', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (503, 507), 'mention': 'ADNI', 'identifier': 'AlzheimerOntology:neuroimaging', 'concept': 'neuroimaging', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (519, 529), 'mention': 'Biomarkers', 'identifier': 'AlzheimerOntology:procedures_using_biomarkers', 'concept': 'thing related to procedure using biomarkers', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (519, 529), 'mention': 'Biomarkers', 'identifier': 'NDDUO:biomarker', 'concept': 'biomarker', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (546, 573), 'mention': 'Neurodegenerative Disorders', 'identifier': 'NDDUO:disorder', 'concept': 'disorder', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (546, 573), 'mention': 'Neurodegenerative Disorders', 'identifier': 'NDDUO:neurodegenerative_disease', 'concept': 'neurodegenerative disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (564, 573), 'mention': 'Disorders', 'identifier': 'NDDUO:disorder', 'concept': 'disorder', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (652, 680), 'mention': 'positron emission tomography', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (682, 685), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (691, 701), 'mention': 'biomarkers', 'identifier': 'AlzheimerOntology:procedures_using_biomarkers', 'concept': 'thing related to procedure using biomarkers', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (691, 701), 'mention': 'biomarkers', 'identifier': 'NDDUO:biomarker', 'concept': 'biomarker', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (720, 729), 'mention': 'cognitive', 'identifier': 'AlzheimerOntology:Cognitive_Tests', 'concept': 'Cognitive Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (763, 767), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (804, 807), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (808, 811), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (867, 871), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (892, 895), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (896, 899), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (922, 939), 'mention': 'cognitive decline', 'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline', 'concept': 'Moderate cognitive Decline', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (922, 939), 'mention': 'cognitive decline', 'identifier': 'AlzheimerOntology:mental_disorder', 'concept': 'mental disorder', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (922, 931), 'mention': 'cognitive', 'identifier': 'AlzheimerOntology:Cognitive_Tests', 'concept': 'Cognitive Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (950, 954), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (964, 968), 'mention': 'risk', 'identifier': 'NDDUO:Risk_factor', 'concept': 'Risk factor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1006, 1009), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1010, 1013), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1028, 1032), 'mention': 'ADNI', 'identifier': 'AlzheimerOntology:neuroimaging', 'concept': 'neuroimaging', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1123, 1126), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1127, 1130), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1139, 1143), 'mention': 'ADNI', 'identifier': 'AlzheimerOntology:neuroimaging', 'concept': 'neuroimaging', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1232, 1236), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1237, 1241), 'mention': 'risk', 'identifier': 'NDDUO:Risk_factor', 'concept': 'Risk factor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1277, 1280), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1281, 1284), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1322, 1326), 'mention': 'ADNI', 'identifier': 'AlzheimerOntology:neuroimaging', 'concept': 'neuroimaging', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1348, 1365), 'mention': 'cognitive decline', 'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline', 'concept': 'Moderate cognitive Decline', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1348, 1365), 'mention': 'cognitive decline', 'identifier': 'AlzheimerOntology:mental_disorder', 'concept': 'mental disorder', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1348, 1357), 'mention': 'cognitive', 'identifier': 'AlzheimerOntology:Cognitive_Tests', 'concept': 'Cognitive Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1397, 1400), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1401, 1404), 'mention': 'PET', 'identifier': 'AlzheimerOntology:Positron_emission_tomography', 'concept': 'Positron emission tomography', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1460, 1464), 'mention': 'BIN1', 'identifier': 'AlzheimerOntology:BIN1', 'concept': 'BIN1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1476, 1478), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1479, 1483), 'mention': 'risk', 'identifier': 'NDDUO:Risk_factor', 'concept': 'Risk factor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1521, 1524), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (0, 19), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (0, 11), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (0, 9), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (12, 19), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (12, 19), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (20, 24), 'mention': 'drug', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (107, 126), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (107, 118), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (107, 116), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (119, 126), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (119, 126), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (128, 130), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (154, 158), 'mention': 'rate', 'identifier': 'NDDUO:rate', 'concept': 'rate', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (164, 174), 'mention': 'treatments', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (164, 174), 'mention': 'treatments', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (230, 235), 'mention': 'drugs', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (239, 254), 'mention': 'clinical trials', 'identifier': 'NDDUO:Clinical_trial', 'concept': 'thing related to clinical trial', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (239, 247), 'mention': 'clinical', 'identifier': 'NDDUO:Clinical', 'concept': 'Clinical thing', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (263, 272), 'mention': 'treatment', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (263, 272), 'mention': 'treatment', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (276, 278), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (349, 364), 'mention': 'clinical trials', 'identifier': 'NDDUO:Clinical_trial', 'concept': 'thing related to clinical trial', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (349, 357), 'mention': 'clinical', 'identifier': 'NDDUO:Clinical', 'concept': 'Clinical thing', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (377, 382), 'mention': 'drugs', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (466, 468), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (473, 483), 'mention': 'treatments', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (473, 483), 'mention': 'treatments', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (487, 494), 'mention': 'Phase 3', 'identifier': 'NDDUO:phase_3', 'concept': 'phase 3', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (509, 516), 'mention': 'Phase 2', 'identifier': 'NDDUO:phase_2', 'concept': 'phase 2', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (528, 535), 'mention': 'Phase 1', 'identifier': 'NDDUO:phase_1', 'concept': 'phase 1', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (553, 558), 'mention': 'drugs', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (610, 612), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (632, 639), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (632, 639), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (673, 682), 'mention': 'cognitive', 'identifier': 'AlzheimerOntology:Cognitive_Tests', 'concept': 'Cognitive Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (714, 719), 'mention': 'drugs', 'identifier': 'NDDUO:drug', 'concept': 'drug', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (746, 771), 'mention': 'neuropsychiatric symptoms', 'identifier': 'AlzheimerOntology:Neuropsychiatric_symptoms', 'concept': 'Neuropsychiatric symptom', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (746, 771), 'mention': 'neuropsychiatric symptoms', 'identifier': 'AlzheimerOntology:psychological_symptom', 'concept': 'psychological symptom', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (763, 771), 'mention': 'symptoms', 'identifier': 'NDDUO:Symptoms', 'concept': 'Symptom or sign', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (837, 846), 'mention': 'processes', 'identifier': 'obo:BFO_0000015', 'concept': 'process', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (837, 846), 'mention': 'processes', 'identifier': 'span:Process', 'concept': 'process', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (851, 855), 'mention': 'more', 'identifier': 'AlzheimerOntology:Memory_orientation_screening_test', 'concept': 'Memory Orientation Screening Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (869, 879), 'mention': 'biomarkers', 'identifier': 'AlzheimerOntology:procedures_using_biomarkers', 'concept': 'thing related to procedure using biomarkers', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (869, 879), 'mention': 'biomarkers', 'identifier': 'NDDUO:biomarker', 'concept': 'biomarker', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (884, 888), 'mention': 'more', 'identifier': 'AlzheimerOntology:Memory_orientation_screening_test', 'concept': 'Memory Orientation Screening Test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (981, 990), 'mention': 'treatment', 'identifier': 'AlzheimerOntology:Intervention', 'concept': 'Intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (981, 990), 'mention': 'treatment', 'identifier': 'NDDUO:Intervention', 'concept': 'Thing related to intervention', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (994, 996), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (4, 6), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (7, 10), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (11, 15), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (70, 73), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (77, 86), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (87, 90), 'mention': 'Tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (140, 159), 'mention': \"Alzheimer's disease\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (140, 151), 'mention': \"Alzheimer's\", 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (140, 149), 'mention': 'Alzheimer', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (152, 159), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (152, 159), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (161, 163), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (169, 174), 'mention': 'other', 'identifier': 'obo:IAO_0000230', 'concept': 'other', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (175, 186), 'mention': 'tauopathies', 'identifier': 'obo:ND_0000151', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (175, 186), 'mention': 'tauopathies', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (212, 215), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (216, 227), 'mention': 'aggregation', 'identifier': 'NDDUO:Cluster', 'concept': 'Cluster', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (287, 290), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (291, 299), 'mention': 'filament', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (300, 305), 'mention': 'cores', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (358, 360), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (361, 364), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (365, 369), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (464, 474), 'mention': 'antibodies', 'identifier': 'AlzheimerOntology:antibody', 'concept': 'antibody', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (493, 495), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (496, 499), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (500, 504), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (505, 514), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (525, 527), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (528, 541), 'mention': 'tau pathology', 'identifier': 'AlzheimerOntology:tauopathy', 'concept': 'tauopathy', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (528, 531), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (547, 549), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (550, 553), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (554, 558), 'mention': 'core', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (571, 582), 'mention': 'aggregation', 'identifier': 'NDDUO:Cluster', 'concept': 'Cluster', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (608, 611), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (674, 677), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (689, 694), 'mention': 'brain', 'identifier': 'obo:FMA_50801', 'concept': 'Brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (689, 694), 'mention': 'brain', 'identifier': 'AlzheimerOntology:brain', 'concept': 'brain', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (722, 741), 'mention': 'cerebrospinal fluid', 'identifier': 'AlzheimerOntology:cerebrospinal_fluid', 'concept': 'cerebrospinal fluid', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (743, 746), 'mention': 'CSF', 'identifier': 'AlzheimerOntology:Cerebospinal_Fluid', 'concept': 'protein circulating in Cerebospinal Fluid', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (743, 746), 'mention': 'CSF', 'identifier': 'AlzheimerOntology:Cerebospinal_fluid_test', 'concept': 'Cerebospinal fluid test', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (743, 746), 'mention': 'CSF', 'identifier': 'AlzheimerOntology:cerebrospinal_fluid', 'concept': 'cerebrospinal fluid', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (743, 746), 'mention': 'CSF', 'identifier': 'AlzheimerOntology:macrophage_colony_stimulating_factor', 'concept': 'macrophage colony stimulating factor', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (767, 769), 'mention': 'AD', 'identifier': 'AlzheimerOntology:Subtypes', 'concept': 'Alzheimer disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (835, 840), 'mention': 'assay', 'identifier': 'obo:OBI_0000070', 'concept': 'assay', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (868, 876), 'mention': 'filament', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (877, 882), 'mention': 'cores', 'identifier': 'obo:IAO_0000224', 'concept': 'core', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (886, 911), 'mention': 'corticobasal degeneration', 'identifier': 'obo:ND_0000169', 'concept': 'corticobasal degeneration', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (929, 936), 'mention': 'disease', 'identifier': 'obo:OGMS_0000031', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (929, 936), 'mention': 'disease', 'identifier': 'NDDUO:disease', 'concept': 'disease', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (967, 976), 'mention': 'filaments', 'identifier': 'AlzheimerOntology:Filaments', 'concept': 'Filament', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1023, 1031), 'mention': 'document', 'identifier': 'obo:IAO_0000310', 'concept': 'document', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1047, 1055), 'mention': 'modeling', 'identifier': 'obo:NBO_0000215', 'concept': 'observational learning', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1047, 1055), 'mention': 'modeling', 'identifier': 'NDDUO:model', 'concept': 'model', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1056, 1059), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1060, 1071), 'mention': 'aggregation', 'identifier': 'NDDUO:Cluster', 'concept': 'Cluster', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1135, 1138), 'mention': 'tau', 'identifier': 'AlzheimerOntology:t_tau', 'concept': 't-tau', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1156, 1165), 'mention': 'biomarker', 'identifier': 'AlzheimerOntology:procedures_using_biomarkers', 'concept': 'thing related to procedure using biomarkers', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n",
      "{'span': (1156, 1165), 'mention': 'biomarker', 'identifier': 'NDDUO:biomarker', 'concept': 'biomarker', 'type': '', 'annotator': 'NIO'}\n",
      "--------\n"
     ]
    }
   ],
   "source": [
    "##  3.2: iterate each article to create the annotation \n",
    "article_path = \"/Users/yidesdo21/Projects/inputs/articles/04_ptc_ten_recent/articles-txt-format/\" \n",
    "# article_path = \"/Users/yidesdo21/Projects/inputs/articles/03_tests_for_dictionary/\"\n",
    "article_num = len(article_ids)\n",
    "titles = dict()\n",
    "\n",
    "for i in range(article_num):  # iteratre over each of the i[th] article\n",
    "    with open(article_path+str(article_ids[i])+\".txt\") as f:  # use article ids here\n",
    "        article = f.readlines()\n",
    "        \n",
    "    # for the i[th] article, get the lists of mention ids, starting and ending indices\n",
    "    mention_ids_for_i = mention_ids[i]\n",
    "    start_ind_for_i = start_ind[i]\n",
    "    end_ind_for_i = end_ind[i]\n",
    "    anno_len = len(mention_ids_for_i)\n",
    "    \n",
    "    ## step 4: visualize the text span with the annotations by using spaCy visualizer\n",
    "    # create the list of dictionaries as the input for spaCy visualizer\n",
    "    # ex = [{\"text\": \"But Google is starting from behind.\",\n",
    "    #        \"ents\": [{\"start\": 4, \"end\": 10, \"label\": \"ORG\"}],\n",
    "    #        \"title\": \"Test\"}]\n",
    "    # html = displacy.render(ex, style=\"ent\", manual=True, options={\"colors\":{\"ORG\":\"yellow\"}})\n",
    "\n",
    "    article_dict = dict() \n",
    "    article_dict_text = dict()\n",
    "    article_dict[\"title\"] = article_ids[i]   \n",
    "    article_dict[\"text\"] = article[0]  # article is list of string, [\"article\"]\n",
    "    article_dict_text[\"title\"] = article_ids[i]   \n",
    "    article_dict_text[\"text\"] = article[0]  # article is list of string, [\"article\"]    \n",
    "    \n",
    "    title_mapping = article_ids[i].split(\"_\")\n",
    "    if len(title_mapping) > 1:   ## this is for the database_identifier format only\n",
    "        titles[title_mapping[1]] = article_ids[i]   # to help the PTC titles to map from identifiers to the database_identfiier\n",
    "    \n",
    "    ents_list = list()\n",
    "    ents_list_text = list()  # for docs_text\n",
    "\n",
    "    ## there are duplications, need to filter; no need to filter if using spaCy visualizer, will overlay \n",
    "    # NDDUO:Study_type 549 554 study\n",
    "    # ----------\n",
    "    # NDDUO:Study_type 549 554 study\n",
    "\n",
    "    start_end = set()  # use this to avoid the duplications in the starting-ending range \n",
    "    \n",
    "    for anno_cnt in range(anno_len):  # iterate over all entity annotations in the i[th] article \n",
    "        mentioned_id = mention_ids_for_i[anno_cnt]\n",
    "        start_index = start_ind_for_i[anno_cnt]\n",
    "        end_index = end_ind_for_i[anno_cnt]\n",
    "        mentioned_entity = article[0][start_index:end_index]\n",
    "        canonical = token_cano[mentioned_id]\n",
    "        \n",
    "        if (start_index,end_index) not in start_end:\n",
    "            start_end.add((start_index,end_index))\n",
    "            ent = dict()\n",
    "            ent[\"start\"] = start_index\n",
    "            ent[\"end\"] = end_index\n",
    "            ent[\"label\"] = \"\"   # for illustration reasons\n",
    "#             ent[\"label\"] = mentioned_id+\"|\"+canonical  # change mentioned_entity into canonical in the xml dictionary\n",
    "            ents_list.append(ent)                             # the labels can only be in uppercase\n",
    "\n",
    "        ent_text = dict()   # this part is not affected because it is for the json not for the displacy\n",
    "        ent_text[\"span\"] = start_index, end_index\n",
    "        ent_text[\"mention\"] = mentioned_entity\n",
    "        ent_text[\"identifier\"] = mentioned_id    # the mention after grounding: ontological identifier\n",
    "        ent_text[\"concept\"] = canonical         # the mention after grounding: ontological concept\n",
    "        ent_text[\"type\"] = \"\"\n",
    "        ent_text[\"annotator\"] = \"NIO\"\n",
    "        if ent_text not in ents_list_text:\n",
    "#             print(ent_text)\n",
    "#             print(\"--------\")\n",
    "            ents_list_text.append(ent_text)  \n",
    "        \n",
    "    article_dict[\"ents\"] = ents_list \n",
    "    article_dict_text[\"ents\"] = ents_list_text\n",
    "\n",
    "    docs.append(article_dict)   # this has to be outside of the articles iteration\n",
    "    docs_text.append(article_dict_text)  # similar to docs, but have mentioned_entities\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "e889d7d1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "ae13f76a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# docs_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b8bed079",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "255d45d5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'title': 'NLM_31721178',\n",
       "  'text': \"Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brain.The constituent paired helical filaments (PHFs) in neurofibrillary tangles are insoluble intracellular deposits central to the development of Alzheimer's disease (AD) and other tauopathies. Full-length tau requires the addition of anionic cofactors such as heparin to enhance assembly. We have shown that a fragment from the proteolytically stable core of the PHF, tau 297-391 known as 'dGAE', spontaneously forms cross-β-containing PHFs and straight filaments under physiological conditions. Here, we have analysed and compared the structures of the filaments formed by dGAE in\\xa0vitro with those deposited in the brains of individuals diagnosed with AD. We show that dGAE forms PHFs that share a macromolecular structure similar to those found in brain tissue. Thus, dGAEs may serve as a model system for studying core domain assembly and for screening for inhibitors of tau aggregation.\",\n",
       "  'ents': [{'span': (0, 3),\n",
       "    'mention': 'Tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (20, 29),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (58, 62),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (81, 90),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (94, 113),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (94, 105),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (94, 103),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (106, 113),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (106, 113),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (114, 119),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (114, 119),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (151, 160),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (171, 194),\n",
       "    'mention': 'neurofibrillary tangles',\n",
       "    'identifier': 'AlzheimerOntology:neurofibrillary_tangle',\n",
       "    'concept': 'neurofibrillary tangle',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (187, 194),\n",
       "    'mention': 'tangles',\n",
       "    'identifier': 'AlzheimerOntology:Tangles',\n",
       "    'concept': 'Tangle',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (262, 281),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (262, 273),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (262, 271),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (274, 281),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (274, 281),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (283, 285),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (291, 296),\n",
       "    'mention': 'other',\n",
       "    'identifier': 'obo:IAO_0000230',\n",
       "    'concept': 'other',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (297, 308),\n",
       "    'mention': 'tauopathies',\n",
       "    'identifier': 'obo:ND_0000151',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (297, 308),\n",
       "    'mention': 'tauopathies',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (322, 325),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (468, 472),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (485, 488),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (571, 580),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (671, 680),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (733, 739),\n",
       "    'mention': 'brains',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (733, 739),\n",
       "    'mention': 'brains',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (770, 772),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (867, 879),\n",
       "    'mention': 'brain tissue',\n",
       "    'identifier': 'AlzheimerOntology:brain_tissue',\n",
       "    'concept': 'brain tissue',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (867, 872),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (867, 872),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (908, 913),\n",
       "    'mention': 'model',\n",
       "    'identifier': 'obo:NBO_0000215',\n",
       "    'concept': 'observational learning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (908, 913),\n",
       "    'mention': 'model',\n",
       "    'identifier': 'NDDUO:model',\n",
       "    'concept': 'model',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (925, 933),\n",
       "    'mention': 'studying',\n",
       "    'identifier': 'NDDUO:Study_type',\n",
       "    'concept': 'clinical trial study',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (934, 938),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (963, 972),\n",
       "    'mention': 'screening',\n",
       "    'identifier': 'NDDUO:Screening',\n",
       "    'concept': 'Screening',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (977, 987),\n",
       "    'mention': 'inhibitors',\n",
       "    'identifier': 'NDDUO:inhibitor',\n",
       "    'concept': 'inhibitor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (991, 994),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (995, 1006),\n",
       "    'mention': 'aggregation',\n",
       "    'identifier': 'NDDUO:Cluster',\n",
       "    'concept': 'Cluster',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'CCC_000653155500009',\n",
       "  'text': \"An excellent electrochemical aptasensor for amyloid-beta oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events.An excellent aptasensor for electrochemical detection of amyloid-beta oligomers (A beta Os) at trace levels was fabricated based on a triple-helix aptamer switch (THAS) via target-triggered signal transduction DNA displacement events. Specifically, a single-stranded anti-A beta O aptamer (Apt) carrying two symmetrical arm segments was first attached via Au-S binding to an Au electrode. Gold nanoparticle (GNP)-tagged signal transduction probes (GNP-STPs) were simultaneously hybridized with the two arm segments of the Apt, and a rigid THAS was formed on the Au electrode. Compared to the conventional hybrid, the number of GNPs on the Au electrode increased significantly with the THAS, effectively improving the stability of the Apt to avoid lodging. Trithiocyanuric acid (TA) was utilized to further gather the GNPs and form network-like TA/GNPs. As a result, the differential pulse voltammetry (DPV) response of GNPs was clearly enhanced. When A beta Os were present, target-triggered signal transduction DNA displacement events were carried out from THAS via the reaction of the Apt with the A beta Os, which caused the GNP-STP to dissociate from the Au electrode, and thus a significant reduction in the DPV response was observed. The assay was able to sensitively detect trace A beta Os by monitoring the A beta O-controlled DPV response change. It exhibited a wide linear range from 1 fM to 10 pM with a low detection limit of 0.5 fM, and was successfully employed for the determination of A beta Os in 20 serum samples, with good recovery. Moreover, the developed assay can provide a sensitive and selective platform for many studies or investigations related to Alzheimer's disease (AD) monitoring and treatment.\",\n",
       "  'ents': [{'span': (44, 56),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (44, 51),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (228, 240),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (228, 235),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1010, 1014),\n",
       "    'mention': 'like',\n",
       "    'identifier': 'obo:NBO_0000282',\n",
       "    'concept': 'liking',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1415, 1420),\n",
       "    'mention': 'assay',\n",
       "    'identifier': 'obo:OBI_0000070',\n",
       "    'concept': 'assay',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1694, 1701),\n",
       "    'mention': 'samples',\n",
       "    'identifier': 'NDDUO:Sampling',\n",
       "    'concept': 'Sampling',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1747, 1752),\n",
       "    'mention': 'assay',\n",
       "    'identifier': 'obo:OBI_0000070',\n",
       "    'concept': 'assay',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1804, 1808),\n",
       "    'mention': 'many',\n",
       "    'identifier': 'AlzheimerOntology:Memory_orientation_screening_test',\n",
       "    'concept': 'Memory Orientation Screening Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1809, 1816),\n",
       "    'mention': 'studies',\n",
       "    'identifier': 'NDDUO:Study_type',\n",
       "    'concept': 'clinical trial study',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1846, 1865),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1846, 1857),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1846, 1855),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1858, 1865),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1858, 1865),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1867, 1869),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1886, 1895),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1886, 1895),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'CCC_000637925000033',\n",
       "  'text': 'Glycoengineering artificial receptors for microglia to phagocytose A beta aggregates.Oligomeric and fibrillar amyloid-beta (A beta) are principally internalized via receptor-mediated endocytosis (RME) by microglia, the main scavenger of A beta in the brain. Nevertheless, the inflammatory cascade will be evoked after vast A beta aggregate binding to pattern recognition receptors on the cell membrane, which then significantly decreases the expression of these receptors and further deteriorate A beta deposition. This vicious circle will weaken the ability of microglia for A beta elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial membranes with ThS as artificial A beta receptors to promote microglia to phagocytose A beta aggregates. Additionally, to circumvent the undesirable immune response during the process of the bioorthogonal chemistry reaction and A beta-microglial interaction, Mn-porphyrin metal-organic frameworks (Mn-MOFs) with superoxide dismutase (SOD) and catalase (CAT) mimic activity are employed to carry N-azidoacetylmannosamine (AcManNAz) and eradicate over-expressed reactive oxygen species (ROSs). The artificial A beta receptors independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with antioxidant properties can synergistically promote the phagocytosis and clearance of A beta with significantly enhanced activity and negligible adverse effects. The present study will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for other disease intervention associated with receptor starvation.',\n",
       "  'ents': [{'span': (28, 37),\n",
       "    'mention': 'receptors',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (42, 51),\n",
       "    'mention': 'microglia',\n",
       "    'identifier': 'AlzheimerOntology:Microglia',\n",
       "    'concept': 'Microglia',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (110, 122),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (110, 117),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (165, 173),\n",
       "    'mention': 'receptor',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (183, 194),\n",
       "    'mention': 'endocytosis',\n",
       "    'identifier': 'AlzheimerOntology:Endocytosis',\n",
       "    'concept': 'Endocytosis',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (204, 213),\n",
       "    'mention': 'microglia',\n",
       "    'identifier': 'AlzheimerOntology:Microglia',\n",
       "    'concept': 'Microglia',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (251, 256),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (251, 256),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (276, 296),\n",
       "    'mention': 'inflammatory cascade',\n",
       "    'identifier': 'AlzheimerOntology:inflammation',\n",
       "    'concept': 'inflammation',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (276, 288),\n",
       "    'mention': 'inflammatory',\n",
       "    'identifier': 'AlzheimerOntology:inflammation',\n",
       "    'concept': 'inflammation',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (371, 380),\n",
       "    'mention': 'receptors',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (393, 401),\n",
       "    'mention': 'membrane',\n",
       "    'identifier': 'AlzheimerOntology:Membrane',\n",
       "    'concept': 'Membrane',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (462, 471),\n",
       "    'mention': 'receptors',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (562, 571),\n",
       "    'mention': 'microglia',\n",
       "    'identifier': 'AlzheimerOntology:Microglia',\n",
       "    'concept': 'Microglia',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (718, 727),\n",
       "    'mention': 'membranes',\n",
       "    'identifier': 'AlzheimerOntology:Membrane',\n",
       "    'concept': 'Membrane',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (758, 767),\n",
       "    'mention': 'receptors',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (779, 788),\n",
       "    'mention': 'microglia',\n",
       "    'identifier': 'AlzheimerOntology:Microglia',\n",
       "    'concept': 'Microglia',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (894, 901),\n",
       "    'mention': 'process',\n",
       "    'identifier': 'obo:BFO_0000015',\n",
       "    'concept': 'process',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (894, 901),\n",
       "    'mention': 'process',\n",
       "    'identifier': 'span:Process',\n",
       "    'concept': 'process',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1187, 1193),\n",
       "    'mention': 'oxygen',\n",
       "    'identifier': 'AlzheimerOntology:oxygen',\n",
       "    'concept': 'oxygen',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1232, 1241),\n",
       "    'mention': 'receptors',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1327, 1338),\n",
       "    'mention': 'antioxidant',\n",
       "    'identifier': 'AlzheimerOntology:antioxidant',\n",
       "    'concept': 'antioxidant',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1382, 1394),\n",
       "    'mention': 'phagocytosis',\n",
       "    'identifier': 'AlzheimerOntology:phagocytosis',\n",
       "    'concept': 'phagocytosis',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1500, 1505),\n",
       "    'mention': 'study',\n",
       "    'identifier': 'NDDUO:Study_type',\n",
       "    'concept': 'clinical trial study',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1680, 1685),\n",
       "    'mention': 'other',\n",
       "    'identifier': 'obo:IAO_0000230',\n",
       "    'concept': 'other',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1686, 1693),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1686, 1693),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1694, 1706),\n",
       "    'mention': 'intervention',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1694, 1706),\n",
       "    'mention': 'intervention',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1723, 1731),\n",
       "    'mention': 'receptor',\n",
       "    'identifier': 'AlzheimerOntology:Receptors',\n",
       "    'concept': 'Receptor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'NLM_34101788',\n",
       "  'text': \"Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for Alzheimer's disease (AD). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or participant groups; use uniform protocols and outcome measures; and may allow treatment arms to be added or dropped based on interim analyses of outcomes. The EU/US CTAD Task Force discussed the lessons learned from the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) platform trial and the challenges addressed by other platform trials that have launched or are in the planning stages. The landscape of clinical trial platforms in the AD space includes those testing experimental therapies such as DIAN-TU, platforms designed to test multidomain interventions, and those designed to streamline trial recruitment by building trial-ready cohorts. The heterogeneity of the AD patient population, AD drugs, treatment regimens, and analytical methods complicates the design and execution of platform trials, yet Task Force members concluded that platform trials are essential to advance the search for effective AD treatments, including combination therapies.\",\n",
       "  'ents': [{'span': (28, 32),\n",
       "    'mention': 'Drug',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (48, 67),\n",
       "    'mention': \"Alzheimer's Disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (48, 59),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (48, 57),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (60, 67),\n",
       "    'mention': 'Disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (60, 67),\n",
       "    'mention': 'Disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (199, 214),\n",
       "    'mention': 'clinical trials',\n",
       "    'identifier': 'NDDUO:Clinical_trial',\n",
       "    'concept': 'thing related to clinical trial',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (199, 207),\n",
       "    'mention': 'clinical',\n",
       "    'identifier': 'NDDUO:Clinical',\n",
       "    'concept': 'Clinical thing',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (219, 238),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (219, 230),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (219, 228),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (231, 238),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (231, 238),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (240, 242),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (314, 323),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (314, 323),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (349, 355),\n",
       "    'mention': 'groups',\n",
       "    'identifier': 'AlzheimerOntology:control_group_study_arm',\n",
       "    'concept': 'control group study arm',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (369, 378),\n",
       "    'mention': 'protocols',\n",
       "    'identifier': 'obo:OBI_0000272',\n",
       "    'concept': 'protocol',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (383, 399),\n",
       "    'mention': 'outcome measures',\n",
       "    'identifier': 'NDDUO:outcome_measure',\n",
       "    'concept': 'outcome measure',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (383, 390),\n",
       "    'mention': 'outcome',\n",
       "    'identifier': 'AlzheimerOntology:Outcome',\n",
       "    'concept': 'Outcome',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (383, 390),\n",
       "    'mention': 'outcome',\n",
       "    'identifier': 'NDDUO:Outcome',\n",
       "    'concept': 'Thing related to outcome',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (415, 424),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (415, 424),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (482, 490),\n",
       "    'mention': 'outcomes',\n",
       "    'identifier': 'AlzheimerOntology:Outcome',\n",
       "    'concept': 'Outcome',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (482, 490),\n",
       "    'mention': 'outcomes',\n",
       "    'identifier': 'NDDUO:Outcome',\n",
       "    'concept': 'Thing related to outcome',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (540, 547),\n",
       "    'mention': 'learned',\n",
       "    'identifier': 'obo:GO_0007612',\n",
       "    'concept': 'learning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (578, 589),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (578, 587),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (667, 672),\n",
       "    'mention': 'other',\n",
       "    'identifier': 'obo:IAO_0000230',\n",
       "    'concept': 'other',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (722, 730),\n",
       "    'mention': 'planning',\n",
       "    'identifier': 'obo:MF_0000027',\n",
       "    'concept': 'planning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (722, 730),\n",
       "    'mention': 'planning',\n",
       "    'identifier': 'obo:OBI_0000260',\n",
       "    'concept': 'plan',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (722, 730),\n",
       "    'mention': 'planning',\n",
       "    'identifier': 'obo:OBI_0000339',\n",
       "    'concept': 'planning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (731, 737),\n",
       "    'mention': 'stages',\n",
       "    'identifier': 'NDDUO:Stages',\n",
       "    'concept': 'thing related to stage',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (756, 770),\n",
       "    'mention': 'clinical trial',\n",
       "    'identifier': 'NDDUO:Clinical_trial',\n",
       "    'concept': 'thing related to clinical trial',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (756, 764),\n",
       "    'mention': 'clinical',\n",
       "    'identifier': 'NDDUO:Clinical',\n",
       "    'concept': 'Clinical thing',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (788, 790),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (899, 912),\n",
       "    'mention': 'interventions',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (899, 912),\n",
       "    'mention': 'interventions',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (989, 996),\n",
       "    'mention': 'cohorts',\n",
       "    'identifier': 'NDDO:NDDO_00000107',\n",
       "    'concept': 'cohort',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (989, 996),\n",
       "    'mention': 'cohorts',\n",
       "    'identifier': 'AlzheimerOntology:Cohort_effect',\n",
       "    'concept': 'Cohort effect',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1023, 1025),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1034, 1044),\n",
       "    'mention': 'population',\n",
       "    'identifier': 'AlzheimerOntology:Populations',\n",
       "    'concept': 'Population',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1046, 1048),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1049, 1054),\n",
       "    'mention': 'drugs',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1056, 1065),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1056, 1065),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1260, 1262),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1263, 1273),\n",
       "    'mention': 'treatments',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1263, 1273),\n",
       "    'mention': 'treatments',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'NLM_33958804',\n",
       "  'text': \"Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease.Selective neurodegeneration is a critical causal factor in Alzheimer's disease (AD); however, the mechanisms that lead some neurons to perish, whereas others remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-nucleus RNA sequencing and discovered that ApoE expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of ApoE-which has a robust genetic linkage to AD-correlated strongly, on a cell-by-cell basis, with immune response pathways in neurons in the brains of wild-type mice, human ApoE knock-in mice and humans with or without AD. Elimination or over-expression of neuronal ApoE revealed a causal relationship among ApoE expression, neuronal MHC-I expression, tau pathology and neurodegeneration. Functional reduction of MHC-I ameliorated tau pathology in ApoE4-expressing primary neurons and in mouse hippocampi expressing pathological tau. These findings suggest a mechanism linking neuronal ApoE expression to MHC-I expression and, subsequently, to tau pathology and selective neurodegeneration.\",\n",
       "  'ents': [{'span': (9, 13),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (9, 13),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (83, 102),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (83, 94),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (83, 92),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (95, 102),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (95, 102),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (162, 181),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (162, 173),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (162, 171),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (174, 181),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (174, 181),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (183, 185),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (227, 234),\n",
       "    'mention': 'neurons',\n",
       "    'identifier': 'NDDUO:Neurons',\n",
       "    'concept': 'Neuron',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (254, 260),\n",
       "    'mention': 'others',\n",
       "    'identifier': 'obo:IAO_0000230',\n",
       "    'concept': 'other',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (365, 372),\n",
       "    'mention': 'nucleus',\n",
       "    'identifier': 'AlzheimerOntology:Nucleus',\n",
       "    'concept': 'Nucleus',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (373, 376),\n",
       "    'mention': 'RNA',\n",
       "    'identifier': 'AlzheimerOntology:RNA',\n",
       "    'concept': 'RNA',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (408, 412),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (408, 412),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (514, 518),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (514, 518),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (557, 559),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (639, 646),\n",
       "    'mention': 'neurons',\n",
       "    'identifier': 'NDDUO:Neurons',\n",
       "    'concept': 'Neuron',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (654, 660),\n",
       "    'mention': 'brains',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (654, 660),\n",
       "    'mention': 'brains',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (674, 678),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (686, 690),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (686, 690),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (700, 704),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (732, 734),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (779, 783),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (779, 783),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (821, 825),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (821, 825),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (865, 878),\n",
       "    'mention': 'tau pathology',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (865, 868),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (944, 957),\n",
       "    'mention': 'tau pathology',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (944, 947),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (986, 993),\n",
       "    'mention': 'neurons',\n",
       "    'identifier': 'NDDUO:Neurons',\n",
       "    'concept': 'Neuron',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1001, 1006),\n",
       "    'mention': 'mouse',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1007, 1017),\n",
       "    'mention': 'hippocampi',\n",
       "    'identifier': 'obo:FMA_62493',\n",
       "    'concept': 'Hippocampus',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1007, 1017),\n",
       "    'mention': 'hippocampi',\n",
       "    'identifier': 'AlzheimerOntology:Hippocampus',\n",
       "    'concept': 'Hippocampus',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1042, 1045),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1099, 1103),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:APOE',\n",
       "    'concept': 'APOE',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1099, 1103),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': 'AlzheimerOntology:ApoE_Protein',\n",
       "    'concept': 'ApoE Protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1157, 1170),\n",
       "    'mention': 'tau pathology',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1157, 1160),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'NLM_33988687',\n",
       "  'text': \"Alzheimer mutant speeds APP transport.APPS198P segregates with rare familial forms of Alzheimer's disease and resides within exon 5, unlike 27 other mutations that reside in exons 16 or 17. In this issue, Zhang et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210313) show that the brains of APPS198P transgenic mice accumulate excess levels of Aβ. In cultured cells, APPS198P undergoes accelerated ER folding, leading to early arrival in late vesicular compartments, thereby enhancing generation of Aβ.\",\n",
       "  'ents': [{'span': (0, 9),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (24, 27),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (24, 27),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (86, 105),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (86, 97),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (86, 95),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (98, 105),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (98, 105),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (143, 148),\n",
       "    'mention': 'other',\n",
       "    'identifier': 'obo:IAO_0000230',\n",
       "    'concept': 'other',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (149, 158),\n",
       "    'mention': 'mutations',\n",
       "    'identifier': 'AlzheimerOntology:mutation',\n",
       "    'concept': 'mutation',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (289, 295),\n",
       "    'mention': 'brains',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (289, 295),\n",
       "    'mention': 'brains',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (319, 323),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (359, 373),\n",
       "    'mention': 'cultured cells',\n",
       "    'identifier': 'AlzheimerOntology:Cell_cultures',\n",
       "    'concept': 'Cell culture',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'CCC_000647663200001',\n",
       "  'text': 'Impairment of visual cortical plasticity by amyloid-beta species.Introduction: A variety of transgenic and knock-in mice that express mutant alleles of Amyloid precursor protein (APP) have been used to model the effects of amyloid-beta (A?) on circuit function in Alzheimer?s disease (AD); however phenotypes described in these mice may be affected by expression of mutant APP or proteolytic cleavage products independent of A?. In addition, the effects of mutant APP expression are attributed to elevated expression of the amyloidogenic, 42-amino acid-long species of A? (A?42) associated with amyloid plaque accumulation in AD, though elevated concentrations of A?40, an A? species produced with normal synaptic activity, may also affect neural function. Methods: To explore the effects of elevated expression of A? on synaptic function in vivo, we assessed visual system plasticity in transgenic mice that express and secrete A? throughout the brain in the absence of APP overexpression. Transgenic mice that express either A?40 or A?42 were assayed for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation. Results: Using two complementary approaches to measure the plastic response to monocular deprivation, we find that male and female mice that express either 40- or 42-amino acid?long A? species demonstrate a plasticity defect comparable to that elicited in transgenic mice that express mutant alleles of APP and Presenilin 1 (APP/PS1 mice). Conclusions: These data support the hypothesis that mutant APP-driven plasticity impairment in mouse models of AD is mediated by production and accumulation of A?. Moreover, these findings suggest that soluble species of A? are capable of modulating synaptic plasticity, likely independent of any aggregation. These findings may have implications for the role of soluble species of A? in both development and disease settings.',\n",
       "  'ents': [{'span': (44, 56),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (44, 51),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (116, 120),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (152, 177),\n",
       "    'mention': 'Amyloid precursor protein',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (152, 159),\n",
       "    'mention': 'Amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (170, 177),\n",
       "    'mention': 'protein',\n",
       "    'identifier': 'AlzheimerOntology:protein',\n",
       "    'concept': 'protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (179, 182),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (179, 182),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (202, 207),\n",
       "    'mention': 'model',\n",
       "    'identifier': 'obo:NBO_0000215',\n",
       "    'concept': 'observational learning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (202, 207),\n",
       "    'mention': 'model',\n",
       "    'identifier': 'NDDUO:model',\n",
       "    'concept': 'model',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (223, 235),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (223, 230),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (252, 260),\n",
       "    'mention': 'function',\n",
       "    'identifier': 'obo:BFO_0000034',\n",
       "    'concept': 'function',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (252, 260),\n",
       "    'mention': 'function',\n",
       "    'identifier': 'snap:Function',\n",
       "    'concept': 'function',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (264, 283),\n",
       "    'mention': 'Alzheimer?s disease',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (264, 275),\n",
       "    'mention': 'Alzheimer?s',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (264, 273),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (276, 283),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (276, 283),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (285, 287),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (298, 308),\n",
       "    'mention': 'phenotypes',\n",
       "    'identifier': 'obo:OGMS_0000023',\n",
       "    'concept': 'phenotype',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (328, 332),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (373, 376),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (373, 376),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (464, 467),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (464, 467),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (595, 609),\n",
       "    'mention': 'amyloid plaque',\n",
       "    'identifier': 'AlzheimerOntology:presence_of_amyloid_plaque',\n",
       "    'concept': 'presence of amyloid plaque',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (595, 602),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (603, 609),\n",
       "    'mention': 'plaque',\n",
       "    'identifier': 'AlzheimerOntology:presence_of_amyloid_plaque',\n",
       "    'concept': 'presence of amyloid plaque',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (603, 609),\n",
       "    'mention': 'plaque',\n",
       "    'identifier': 'AlzheimerOntology:senile_plaque',\n",
       "    'concept': 'presence of senile plaque',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (626, 628),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (747, 755),\n",
       "    'mention': 'function',\n",
       "    'identifier': 'obo:BFO_0000034',\n",
       "    'concept': 'function',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (747, 755),\n",
       "    'mention': 'function',\n",
       "    'identifier': 'snap:Function',\n",
       "    'concept': 'function',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (830, 838),\n",
       "    'mention': 'function',\n",
       "    'identifier': 'obo:BFO_0000034',\n",
       "    'concept': 'function',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (830, 838),\n",
       "    'mention': 'function',\n",
       "    'identifier': 'snap:Function',\n",
       "    'concept': 'function',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (842, 846),\n",
       "    'mention': 'vivo',\n",
       "    'identifier': 'NDDUO:In_vivo',\n",
       "    'concept': 'In vivo thing',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (899, 903),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (947, 952),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (947, 952),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (971, 974),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (971, 974),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1002, 1006),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1045, 1052),\n",
       "    'mention': 'assayed',\n",
       "    'identifier': 'obo:OBI_0000070',\n",
       "    'concept': 'assay',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1276, 1280),\n",
       "    'mention': 'male',\n",
       "    'identifier': 'NDDUO:male',\n",
       "    'concept': 'male',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1285, 1291),\n",
       "    'mention': 'female',\n",
       "    'identifier': 'NDDUO:female',\n",
       "    'concept': 'female',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1292, 1296),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1428, 1432),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1464, 1467),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1464, 1467),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1472, 1484),\n",
       "    'mention': 'Presenilin 1',\n",
       "    'identifier': 'AlzheimerOntology:presenilin_1',\n",
       "    'concept': 'presenilin 1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1472, 1482),\n",
       "    'mention': 'Presenilin',\n",
       "    'identifier': 'AlzheimerOntology:presenilin',\n",
       "    'concept': 'presenilin',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1486, 1489),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1486, 1489),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1494, 1498),\n",
       "    'mention': 'mice',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1560, 1563),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:APP',\n",
       "    'concept': 'APP',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1560, 1563),\n",
       "    'mention': 'APP',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_precursor_protein',\n",
       "    'concept': 'amyloid precursor protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1596, 1608),\n",
       "    'mention': 'mouse models',\n",
       "    'identifier': 'NDDUO:In_vivo_models',\n",
       "    'concept': 'In vivo model',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1596, 1601),\n",
       "    'mention': 'mouse',\n",
       "    'identifier': 'NDDUO:Mouse_',\n",
       "    'concept': 'Mouse',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1602, 1608),\n",
       "    'mention': 'models',\n",
       "    'identifier': 'obo:NBO_0000215',\n",
       "    'concept': 'observational learning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1602, 1608),\n",
       "    'mention': 'models',\n",
       "    'identifier': 'NDDUO:model',\n",
       "    'concept': 'model',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1612, 1614),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1798, 1809),\n",
       "    'mention': 'aggregation',\n",
       "    'identifier': 'NDDUO:Cluster',\n",
       "    'concept': 'Cluster',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1856, 1863),\n",
       "    'mention': 'role of',\n",
       "    'identifier': 'obo:RO_0000081',\n",
       "    'concept': 'role of',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1856, 1860),\n",
       "    'mention': 'role',\n",
       "    'identifier': 'obo:BFO_0000023',\n",
       "    'concept': 'role',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1856, 1860),\n",
       "    'mention': 'role',\n",
       "    'identifier': 'snap:Role',\n",
       "    'concept': 'role',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1910, 1917),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1910, 1917),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'NLM_34060233',\n",
       "  'text': \"The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.INTRODUCTION: The BIN1 rs744373 single nucleotide polymorphism (SNP) is a key genetic risk locus for Alzheimer's disease (AD) associated with tau pathology. Because tau typically accumulates in response to amyloid beta (Aβ), we tested whether BIN1 rs744373 accelerates Aβ-related tau accumulation. METHODS: We included two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI], n\\xa0=\\xa0153; Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER], n\\xa0=\\xa063) with longitudinal (18) F-Flortaucipir positron emission tomography (PET), Aβ biomarkers, and longitudinal cognitive assessments. We assessed whether BIN1 rs744373 was associated with faster tau-PET accumulation at a given level of Aβ and whether faster BIN1 rs744373-associated tau-PET accumulation mediated cognitive decline. RESULTS: BIN1 rs744373 risk-allele carriers showed faster global tau-PET accumulation (ADNI/BioFINDER, P\\xa0<\\xa0.001/P\\xa0<\\xa0.001). We found significant Aβ by rs744373 interactions on global tau-PET change (ADNI: β/standard error [SE]\\xa0=\\xa00.42/0.14, P\\xa0=\\xa00.002; BioFINDER: β/SE\\xa0=\\xa0-0.35/0.15, P\\xa0=\\xa0.021), BIN1 risk-allele carriers showed accelerated tau-PET accumulation at higher Aβ levels. In ADNI, rs744373 effects on cognitive decline were mediated by faster global tau-PET accumulation (β/SE\\xa0=\\xa00.20/0.07, P\\xa0=\\xa0.005). DISCUSSION: BIN1-associated AD risk is potentially driven by accelerated tau accumulation in the face of Aβ.\",\n",
       "  'ents': [{'span': (4, 8),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (18, 37),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (18, 29),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (18, 27),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (30, 37),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (30, 37),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (38, 42),\n",
       "    'mention': 'risk',\n",
       "    'identifier': 'NDDUO:Risk_factor',\n",
       "    'concept': 'Risk factor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (87, 90),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (108, 125),\n",
       "    'mention': 'cognitive decline',\n",
       "    'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline',\n",
       "    'concept': 'Moderate cognitive Decline',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (108, 125),\n",
       "    'mention': 'cognitive decline',\n",
       "    'identifier': 'AlzheimerOntology:mental_disorder',\n",
       "    'concept': 'mental disorder',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (108, 117),\n",
       "    'mention': 'cognitive',\n",
       "    'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "    'concept': 'Cognitive Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (144, 148),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (212, 216),\n",
       "    'mention': 'risk',\n",
       "    'identifier': 'NDDUO:Risk_factor',\n",
       "    'concept': 'Risk factor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (227, 246),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (227, 238),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (227, 236),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (239, 246),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (239, 246),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (248, 250),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (268, 281),\n",
       "    'mention': 'tau pathology',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (268, 271),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (291, 294),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (332, 344),\n",
       "    'mention': 'amyloid beta',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (332, 339),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "    'concept': 'amyloid beta protein',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (369, 373),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (406, 409),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (449, 456),\n",
       "    'mention': 'samples',\n",
       "    'identifier': 'NDDUO:Sampling',\n",
       "    'concept': 'Sampling',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (458, 501),\n",
       "    'mention': \"Alzheimer's Disease Neuroimaging Initiative\",\n",
       "    'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "    'concept': 'neuroimaging',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (458, 477),\n",
       "    'mention': \"Alzheimer's Disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (458, 469),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (458, 467),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (470, 477),\n",
       "    'mention': 'Disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (470, 477),\n",
       "    'mention': 'Disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (478, 490),\n",
       "    'mention': 'Neuroimaging',\n",
       "    'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "    'concept': 'neuroimaging',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (503, 507),\n",
       "    'mention': 'ADNI',\n",
       "    'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "    'concept': 'neuroimaging',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (519, 529),\n",
       "    'mention': 'Biomarkers',\n",
       "    'identifier': 'AlzheimerOntology:procedures_using_biomarkers',\n",
       "    'concept': 'thing related to procedure using biomarkers',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (519, 529),\n",
       "    'mention': 'Biomarkers',\n",
       "    'identifier': 'NDDUO:biomarker',\n",
       "    'concept': 'biomarker',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (546, 573),\n",
       "    'mention': 'Neurodegenerative Disorders',\n",
       "    'identifier': 'NDDUO:disorder',\n",
       "    'concept': 'disorder',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (546, 573),\n",
       "    'mention': 'Neurodegenerative Disorders',\n",
       "    'identifier': 'NDDUO:neurodegenerative_disease',\n",
       "    'concept': 'neurodegenerative disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (564, 573),\n",
       "    'mention': 'Disorders',\n",
       "    'identifier': 'NDDUO:disorder',\n",
       "    'concept': 'disorder',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (652, 680),\n",
       "    'mention': 'positron emission tomography',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (682, 685),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (691, 701),\n",
       "    'mention': 'biomarkers',\n",
       "    'identifier': 'AlzheimerOntology:procedures_using_biomarkers',\n",
       "    'concept': 'thing related to procedure using biomarkers',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (691, 701),\n",
       "    'mention': 'biomarkers',\n",
       "    'identifier': 'NDDUO:biomarker',\n",
       "    'concept': 'biomarker',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (720, 729),\n",
       "    'mention': 'cognitive',\n",
       "    'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "    'concept': 'Cognitive Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (763, 767),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (804, 807),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (808, 811),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (867, 871),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (892, 895),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (896, 899),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (922, 939),\n",
       "    'mention': 'cognitive decline',\n",
       "    'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline',\n",
       "    'concept': 'Moderate cognitive Decline',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (922, 939),\n",
       "    'mention': 'cognitive decline',\n",
       "    'identifier': 'AlzheimerOntology:mental_disorder',\n",
       "    'concept': 'mental disorder',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (922, 931),\n",
       "    'mention': 'cognitive',\n",
       "    'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "    'concept': 'Cognitive Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (950, 954),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (964, 968),\n",
       "    'mention': 'risk',\n",
       "    'identifier': 'NDDUO:Risk_factor',\n",
       "    'concept': 'Risk factor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1006, 1009),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1010, 1013),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1028, 1032),\n",
       "    'mention': 'ADNI',\n",
       "    'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "    'concept': 'neuroimaging',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1123, 1126),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1127, 1130),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1139, 1143),\n",
       "    'mention': 'ADNI',\n",
       "    'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "    'concept': 'neuroimaging',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1232, 1236),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1237, 1241),\n",
       "    'mention': 'risk',\n",
       "    'identifier': 'NDDUO:Risk_factor',\n",
       "    'concept': 'Risk factor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1277, 1280),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1281, 1284),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1322, 1326),\n",
       "    'mention': 'ADNI',\n",
       "    'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "    'concept': 'neuroimaging',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1348, 1365),\n",
       "    'mention': 'cognitive decline',\n",
       "    'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline',\n",
       "    'concept': 'Moderate cognitive Decline',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1348, 1365),\n",
       "    'mention': 'cognitive decline',\n",
       "    'identifier': 'AlzheimerOntology:mental_disorder',\n",
       "    'concept': 'mental disorder',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1348, 1357),\n",
       "    'mention': 'cognitive',\n",
       "    'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "    'concept': 'Cognitive Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1397, 1400),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1401, 1404),\n",
       "    'mention': 'PET',\n",
       "    'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "    'concept': 'Positron emission tomography',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1460, 1464),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': 'AlzheimerOntology:BIN1',\n",
       "    'concept': 'BIN1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1476, 1478),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1479, 1483),\n",
       "    'mention': 'risk',\n",
       "    'identifier': 'NDDUO:Risk_factor',\n",
       "    'concept': 'Risk factor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1521, 1524),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'NLM_34095440',\n",
       "  'text': \"Alzheimer's disease drug development pipeline: 2021.INTRODUCTION: The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. METHODS: We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. DISCUSSION: This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.\",\n",
       "  'ents': [{'span': (0, 19),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (0, 11),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (0, 9),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (12, 19),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (12, 19),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (20, 24),\n",
       "    'mention': 'drug',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (107, 126),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (107, 118),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (107, 116),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (119, 126),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (119, 126),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (128, 130),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (154, 158),\n",
       "    'mention': 'rate',\n",
       "    'identifier': 'NDDUO:rate',\n",
       "    'concept': 'rate',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (164, 174),\n",
       "    'mention': 'treatments',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (164, 174),\n",
       "    'mention': 'treatments',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (230, 235),\n",
       "    'mention': 'drugs',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (239, 254),\n",
       "    'mention': 'clinical trials',\n",
       "    'identifier': 'NDDUO:Clinical_trial',\n",
       "    'concept': 'thing related to clinical trial',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (239, 247),\n",
       "    'mention': 'clinical',\n",
       "    'identifier': 'NDDUO:Clinical',\n",
       "    'concept': 'Clinical thing',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (263, 272),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (263, 272),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (276, 278),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (349, 364),\n",
       "    'mention': 'clinical trials',\n",
       "    'identifier': 'NDDUO:Clinical_trial',\n",
       "    'concept': 'thing related to clinical trial',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (349, 357),\n",
       "    'mention': 'clinical',\n",
       "    'identifier': 'NDDUO:Clinical',\n",
       "    'concept': 'Clinical thing',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (377, 382),\n",
       "    'mention': 'drugs',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (466, 468),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (473, 483),\n",
       "    'mention': 'treatments',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (473, 483),\n",
       "    'mention': 'treatments',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (487, 494),\n",
       "    'mention': 'Phase 3',\n",
       "    'identifier': 'NDDUO:phase_3',\n",
       "    'concept': 'phase 3',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (509, 516),\n",
       "    'mention': 'Phase 2',\n",
       "    'identifier': 'NDDUO:phase_2',\n",
       "    'concept': 'phase 2',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (528, 535),\n",
       "    'mention': 'Phase 1',\n",
       "    'identifier': 'NDDUO:phase_1',\n",
       "    'concept': 'phase 1',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (553, 558),\n",
       "    'mention': 'drugs',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (610, 612),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (632, 639),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (632, 639),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (673, 682),\n",
       "    'mention': 'cognitive',\n",
       "    'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "    'concept': 'Cognitive Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (714, 719),\n",
       "    'mention': 'drugs',\n",
       "    'identifier': 'NDDUO:drug',\n",
       "    'concept': 'drug',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (746, 771),\n",
       "    'mention': 'neuropsychiatric symptoms',\n",
       "    'identifier': 'AlzheimerOntology:Neuropsychiatric_symptoms',\n",
       "    'concept': 'Neuropsychiatric symptom',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (746, 771),\n",
       "    'mention': 'neuropsychiatric symptoms',\n",
       "    'identifier': 'AlzheimerOntology:psychological_symptom',\n",
       "    'concept': 'psychological symptom',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (763, 771),\n",
       "    'mention': 'symptoms',\n",
       "    'identifier': 'NDDUO:Symptoms',\n",
       "    'concept': 'Symptom or sign',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (837, 846),\n",
       "    'mention': 'processes',\n",
       "    'identifier': 'obo:BFO_0000015',\n",
       "    'concept': 'process',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (837, 846),\n",
       "    'mention': 'processes',\n",
       "    'identifier': 'span:Process',\n",
       "    'concept': 'process',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (851, 855),\n",
       "    'mention': 'more',\n",
       "    'identifier': 'AlzheimerOntology:Memory_orientation_screening_test',\n",
       "    'concept': 'Memory Orientation Screening Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (869, 879),\n",
       "    'mention': 'biomarkers',\n",
       "    'identifier': 'AlzheimerOntology:procedures_using_biomarkers',\n",
       "    'concept': 'thing related to procedure using biomarkers',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (869, 879),\n",
       "    'mention': 'biomarkers',\n",
       "    'identifier': 'NDDUO:biomarker',\n",
       "    'concept': 'biomarker',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (884, 888),\n",
       "    'mention': 'more',\n",
       "    'identifier': 'AlzheimerOntology:Memory_orientation_screening_test',\n",
       "    'concept': 'Memory Orientation Screening Test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (981, 990),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'AlzheimerOntology:Intervention',\n",
       "    'concept': 'Intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (981, 990),\n",
       "    'mention': 'treatment',\n",
       "    'identifier': 'NDDUO:Intervention',\n",
       "    'concept': 'Thing related to intervention',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (994, 996),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]},\n",
       " {'title': 'NLM_33730588',\n",
       "  'text': \"The AD tau core spontaneously self-assembles and recruits full-length tau to filaments.Tau accumulation is a major pathological hallmark of Alzheimer's disease (AD) and other tauopathies, but the mechanism(s) of tau aggregation remains unclear. Taking advantage of the identification of tau filament cores by cryoelectron microscopy, we demonstrate that the AD tau core possesses the intrinsic ability to spontaneously aggregate in the absence of an inducer, with antibodies generated against AD tau core filaments detecting AD tau pathology. The AD tau core also drives aggregation of full-length wild-type tau, increases seeding potential, and templates abnormal forms of tau present in brain homogenates and antemortem cerebrospinal fluid (CSF) from patients with AD in an ultrasensitive real-time quaking-induced conversion (QuIC) assay. Finally, we show that the filament cores in corticobasal degeneration (CBD) and Pick's disease (PiD) similarly assemble into filaments under physiological conditions. These results document an approach to modeling tau aggregation and have significant implications for in\\xa0vivo investigation of tau transmission and biomarker development.\",\n",
       "  'ents': [{'span': (4, 6),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (7, 10),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (11, 15),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (70, 73),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (77, 86),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (87, 90),\n",
       "    'mention': 'Tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (140, 159),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (140, 151),\n",
       "    'mention': \"Alzheimer's\",\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (140, 149),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (152, 159),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (152, 159),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (161, 163),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (169, 174),\n",
       "    'mention': 'other',\n",
       "    'identifier': 'obo:IAO_0000230',\n",
       "    'concept': 'other',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (175, 186),\n",
       "    'mention': 'tauopathies',\n",
       "    'identifier': 'obo:ND_0000151',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (175, 186),\n",
       "    'mention': 'tauopathies',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (212, 215),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (216, 227),\n",
       "    'mention': 'aggregation',\n",
       "    'identifier': 'NDDUO:Cluster',\n",
       "    'concept': 'Cluster',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (287, 290),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (291, 299),\n",
       "    'mention': 'filament',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (300, 305),\n",
       "    'mention': 'cores',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (358, 360),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (361, 364),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (365, 369),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (464, 474),\n",
       "    'mention': 'antibodies',\n",
       "    'identifier': 'AlzheimerOntology:antibody',\n",
       "    'concept': 'antibody',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (493, 495),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (496, 499),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (500, 504),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (505, 514),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (525, 527),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (528, 541),\n",
       "    'mention': 'tau pathology',\n",
       "    'identifier': 'AlzheimerOntology:tauopathy',\n",
       "    'concept': 'tauopathy',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (528, 531),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (547, 549),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (550, 553),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (554, 558),\n",
       "    'mention': 'core',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (571, 582),\n",
       "    'mention': 'aggregation',\n",
       "    'identifier': 'NDDUO:Cluster',\n",
       "    'concept': 'Cluster',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (608, 611),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (674, 677),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (689, 694),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'obo:FMA_50801',\n",
       "    'concept': 'Brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (689, 694),\n",
       "    'mention': 'brain',\n",
       "    'identifier': 'AlzheimerOntology:brain',\n",
       "    'concept': 'brain',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (722, 741),\n",
       "    'mention': 'cerebrospinal fluid',\n",
       "    'identifier': 'AlzheimerOntology:cerebrospinal_fluid',\n",
       "    'concept': 'cerebrospinal fluid',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (743, 746),\n",
       "    'mention': 'CSF',\n",
       "    'identifier': 'AlzheimerOntology:Cerebospinal_Fluid',\n",
       "    'concept': 'protein circulating in Cerebospinal Fluid',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (743, 746),\n",
       "    'mention': 'CSF',\n",
       "    'identifier': 'AlzheimerOntology:Cerebospinal_fluid_test',\n",
       "    'concept': 'Cerebospinal fluid test',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (743, 746),\n",
       "    'mention': 'CSF',\n",
       "    'identifier': 'AlzheimerOntology:cerebrospinal_fluid',\n",
       "    'concept': 'cerebrospinal fluid',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (743, 746),\n",
       "    'mention': 'CSF',\n",
       "    'identifier': 'AlzheimerOntology:macrophage_colony_stimulating_factor',\n",
       "    'concept': 'macrophage colony stimulating factor',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (767, 769),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'AlzheimerOntology:Subtypes',\n",
       "    'concept': 'Alzheimer disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (835, 840),\n",
       "    'mention': 'assay',\n",
       "    'identifier': 'obo:OBI_0000070',\n",
       "    'concept': 'assay',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (868, 876),\n",
       "    'mention': 'filament',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (877, 882),\n",
       "    'mention': 'cores',\n",
       "    'identifier': 'obo:IAO_0000224',\n",
       "    'concept': 'core',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (886, 911),\n",
       "    'mention': 'corticobasal degeneration',\n",
       "    'identifier': 'obo:ND_0000169',\n",
       "    'concept': 'corticobasal degeneration',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (929, 936),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'obo:OGMS_0000031',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (929, 936),\n",
       "    'mention': 'disease',\n",
       "    'identifier': 'NDDUO:disease',\n",
       "    'concept': 'disease',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (967, 976),\n",
       "    'mention': 'filaments',\n",
       "    'identifier': 'AlzheimerOntology:Filaments',\n",
       "    'concept': 'Filament',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1023, 1031),\n",
       "    'mention': 'document',\n",
       "    'identifier': 'obo:IAO_0000310',\n",
       "    'concept': 'document',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1047, 1055),\n",
       "    'mention': 'modeling',\n",
       "    'identifier': 'obo:NBO_0000215',\n",
       "    'concept': 'observational learning',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1047, 1055),\n",
       "    'mention': 'modeling',\n",
       "    'identifier': 'NDDUO:model',\n",
       "    'concept': 'model',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1056, 1059),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1060, 1071),\n",
       "    'mention': 'aggregation',\n",
       "    'identifier': 'NDDUO:Cluster',\n",
       "    'concept': 'Cluster',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1135, 1138),\n",
       "    'mention': 'tau',\n",
       "    'identifier': 'AlzheimerOntology:t_tau',\n",
       "    'concept': 't-tau',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1156, 1165),\n",
       "    'mention': 'biomarker',\n",
       "    'identifier': 'AlzheimerOntology:procedures_using_biomarkers',\n",
       "    'concept': 'thing related to procedure using biomarkers',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'},\n",
       "   {'span': (1156, 1165),\n",
       "    'mention': 'biomarker',\n",
       "    'identifier': 'NDDUO:biomarker',\n",
       "    'concept': 'biomarker',\n",
       "    'type': '',\n",
       "    'annotator': 'NIO'}]}]"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "ec16843b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def write_to_json(path, doc, span_raw):\n",
    "    \"\"\"write the annotations to the json format\n",
    "    inputs:\n",
    "        path: the path to the output json file\n",
    "        doc: the file to be written to the json format\n",
    "        span_raw: the file name of the raw text spans\n",
    "    output: a json file written in the output path\n",
    "    \"\"\"\n",
    "    options = jsbeautifier.default_options()\n",
    "    options.indent_size = 8\n",
    "    \n",
    "    sorted_doc = sorted(doc, key=lambda d: d['title']) \n",
    "    json_object = jsbeautifier.beautify(json.dumps(sorted_doc), options)\n",
    "\n",
    "    with open(path+span_raw.split(\".\")[0]+'.json', 'w') as fp:\n",
    "        fp.write(json_object)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "329c88f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "result_path = \"/Users/yidesdo21/Projects/outputs/10_ptc_ten_recent/json/\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "10986ad8",
   "metadata": {},
   "outputs": [],
   "source": [
    "write_to_json(result_path, docs_text, output_file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "75a215f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "# options = jsbeautifier.default_options()\n",
    "# options.indent_size = 8"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "9b390d88",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # export docs_text to json: either 1) write a json object outside of the with open... by using json.dumps\n",
    "# #                       or 2) use with open ... and write json.dump within the with open\n",
    "# # docs_text has article, mentioned entity, mentioned id, canonical, and entity text span\n",
    "# # result_path = \"/Users/yidesdo21/Projects/outputs/03_annotation_with_articles/json_with_entity/\"\n",
    "# result_path = \"/Users/yidesdo21/Projects/outputs/10_ptc_ten_recent/json/\"\n",
    "# json_object = jsbeautifier.beautify(json.dumps(docs_text), options)\n",
    "\n",
    "# with open(result_path+output_file.split(\".\")[0]+'.json', 'w') as fp:\n",
    "#     fp.write(json_object)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "id": "88d0201b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'nio_ten_recent_spans_nested_case.txt'"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_file"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4c7ea4f1",
   "metadata": {},
   "source": [
    "### Results from the NIO annotator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "9385e286",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><h2 style=\"margin: 0\">NLM_31721178</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (297-391) forms \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that structurally mimic the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of paired helical \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".The constituent paired helical \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (PHFs) in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurofibrillary tangles\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are insoluble intracellular deposits central to the development of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tauopathies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Full-length \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " requires the addition of anionic cofactors such as heparin to enhance assembly. We have shown that a fragment from the proteolytically stable \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of the PHF, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " 297-391 known as 'dGAE', spontaneously forms cross-β-containing PHFs and straight \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " under physiological conditions. Here, we have analysed and compared the structures of the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " formed by dGAE in vitro with those deposited in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brains\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of individuals diagnosed with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". We show that dGAE forms PHFs that share a macromolecular structure similar to those found in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Thus, dGAEs may serve as a \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    model\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " system for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    studying\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " domain assembly and for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    screening\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    inhibitors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000653155500009</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">An excellent electrochemical aptasensor for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events.An excellent aptasensor for electrochemical detection of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " oligomers (A beta Os) at trace levels was fabricated based on a triple-helix aptamer switch (THAS) via target-triggered signal transduction DNA displacement events. Specifically, a single-stranded anti-A beta O aptamer (Apt) carrying two symmetrical arm segments was first attached via Au-S binding to an Au electrode. Gold nanoparticle (GNP)-tagged signal transduction probes (GNP-STPs) were simultaneously hybridized with the two arm segments of the Apt, and a rigid THAS was formed on the Au electrode. Compared to the conventional hybrid, the number of GNPs on the Au electrode increased significantly with the THAS, effectively improving the stability of the Apt to avoid lodging. Trithiocyanuric acid (TA) was utilized to further gather the GNPs and form network-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    like\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " TA/GNPs. As a result, the differential pulse voltammetry (DPV) response of GNPs was clearly enhanced. When A beta Os were present, target-triggered signal transduction DNA displacement events were carried out from THAS via the reaction of the Apt with the A beta Os, which caused the GNP-STP to dissociate from the Au electrode, and thus a significant reduction in the DPV response was observed. The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assay\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " was able to sensitively detect trace A beta Os by monitoring the A beta O-controlled DPV response change. It exhibited a wide linear range from 1 fM to 10 pM with a low detection limit of 0.5 fM, and was successfully employed for the determination of A beta Os in 20 serum \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    samples\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", with good recovery. Moreover, the developed \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assay\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " can provide a sensitive and selective platform for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    many\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    studies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " or investigations related to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") monitoring and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000637925000033</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Glycoengineering artificial \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to phagocytose A beta aggregates.Oligomeric and fibrillar \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (A beta) are principally internalized via \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-mediated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    endocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (RME) by \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", the main scavenger of A beta in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Nevertheless, the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    inflammatory cascade\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " will be evoked after vast A beta aggregate binding to pattern recognition \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " on the cell \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    membrane\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", which then significantly decreases the expression of these \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and further deteriorate A beta deposition. This vicious circle will weaken the ability of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for A beta elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    membranes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " with ThS as artificial A beta \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to promote \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to phagocytose A beta aggregates. Additionally, to circumvent the undesirable immune response during the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    process\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of the bioorthogonal chemistry reaction and A beta-microglial interaction, Mn-porphyrin metal-organic frameworks (Mn-MOFs) with superoxide dismutase (SOD) and catalase (CAT) mimic activity are employed to carry N-azidoacetylmannosamine (AcManNAz) and eradicate over-expressed reactive \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxygen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " species (ROSs). The artificial A beta \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    antioxidant\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " properties can synergistically promote the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    phagocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and clearance of A beta with significantly enhanced activity and negligible adverse effects. The present \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    study\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    intervention\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " associated with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " starvation.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34101788</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Platform Trials to Expedite \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Drug\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " Development in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's Disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ": A Report from the EU/US CTAD Task Force.A diverse range of platforms has been established to increase the efficiency and speed of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trials\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "). These platforms enable parallel assessment of multiple therapeutics, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " regimens, or participant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    groups\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "; use uniform \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    protocols\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    outcome measures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "; and may allow \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " arms to be added or dropped based on interim analyses of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    outcomes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The EU/US CTAD Task Force discussed the lessons \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    learned\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " from the Dominantly Inherited \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " Network Trials Unit (DIAN-TU) platform trial and the challenges addressed by \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " platform trials that have launched or are in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    planning\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    stages\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The landscape of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trial\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " platforms in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " space includes those testing experimental therapies such as DIAN-TU, platforms designed to test multidomain \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interventions\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", and those designed to streamline trial recruitment by building trial-ready \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cohorts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The heterogeneity of the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " patient \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    population\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " regimens, and analytical methods complicates the design and execution of platform trials, yet Task Force members concluded that platform trials are essential to advance the search for effective \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", including combination therapies.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33958804</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Neuronal \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " upregulates MHC-I expression to drive selective \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".Selective \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " is a critical causal factor in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "); however, the mechanisms that lead some \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurons\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to perish, whereas \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    others\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nucleus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " sequencing and discovered that \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-which has a robust genetic linkage to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-correlated strongly, on a cell-by-cell basis, with immune response pathways in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurons\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brains\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of wild-type \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", human \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " knock-in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and humans with or without \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Elimination or over-expression of neuronal \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " revealed a causal relationship among \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expression, neuronal MHC-I expression, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Functional reduction of MHC-I ameliorated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-expressing primary \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurons\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hippocampi\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expressing pathological \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". These findings suggest a mechanism linking neuronal \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expression to MHC-I expression and, subsequently, to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and selective \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33988687</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " mutant speeds \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " transport.APPS198P segregates with rare familial forms of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and resides within exon 5, unlike 27 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mutations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that reside in exons 16 or 17. In this issue, Zhang et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210313) show that the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brains\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of APPS198P transgenic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulate excess levels of Aβ. In \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cultured cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", APPS198P undergoes accelerated ER folding, leading to early arrival in late vesicular compartments, thereby enhancing generation of Aβ.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000647663200001</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Impairment of visual cortical plasticity by \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " species.Introduction: A variety of transgenic and knock-in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express mutant alleles of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amyloid precursor protein\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") have been used to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    model\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " the effects of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (A?) on circuit \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    function\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer?s disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "); however \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    phenotypes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " described in these \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " may be affected by expression of mutant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " or proteolytic cleavage products independent of A?. In addition, the effects of mutant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expression are attributed to elevated expression of the amyloidogenic, 42-amino acid-long species of A? (A?42) associated with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid plaque\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", though elevated concentrations of A?40, an A? species produced with normal synaptic activity, may also affect neural \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    function\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Methods: To explore the effects of elevated expression of A? on synaptic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    function\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vivo\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", we assessed visual system plasticity in transgenic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express and secrete A? throughout the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in the absence of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " overexpression. Transgenic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express either A?40 or A?42 were \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assayed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation. Results: Using two complementary approaches to measure the plastic response to monocular deprivation, we find that \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    male\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    female\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express either 40- or 42-amino acid?long A? species demonstrate a plasticity defect comparable to that elicited in transgenic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express mutant alleles of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Presenilin 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "/PS1 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "). Conclusions: These data support the hypothesis that mutant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-driven plasticity impairment in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse models\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " is mediated by production and accumulation of A?. Moreover, these findings suggest that soluble species of A? are capable of modulating synaptic plasticity, likely independent of any \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". These findings may have implications for the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    role of\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " soluble species of A? in both development and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " settings.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34060233</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " rs744373 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " SNP is associated with faster Aβ-associated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive decline\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".INTRODUCTION: The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " rs744373 single nucleotide polymorphism (SNP) is a key genetic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " locus for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") associated with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Because \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " typically accumulates in response to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (Aβ), we tested whether \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " rs744373 accelerates Aβ-related \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation. METHODS: We included two \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    samples\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's Disease Neuroimaging Initiative\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " [\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "], n = 153; \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Biomarkers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for Identifying \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Neurodegenerative Disorders\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " Early and Reliably [BioFINDER], n = 63) with longitudinal (18) F-Flortaucipir \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    positron emission tomography\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "), Aβ \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    biomarkers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", and longitudinal \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " assessments. We assessed whether \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " rs744373 was associated with faster \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation at a given level of Aβ and whether faster \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " rs744373-associated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation mediated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive decline\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". RESULTS: \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " rs744373 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-allele carriers showed faster global \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "/BioFINDER, P &lt; .001/P &lt; .001). We found significant Aβ by rs744373 interactions on global \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " change (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ": β/standard error [SE] = 0.42/0.14, P = 0.002; BioFINDER: β/SE = -0.35/0.15, P = .021), \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-allele carriers showed accelerated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation at higher Aβ levels. In \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", rs744373 effects on \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive decline\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " were mediated by faster global \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation (β/SE = 0.20/0.07, P = .005). DISCUSSION: \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-associated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " is potentially driven by accelerated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation in the face of Aβ.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34095440</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drug\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " development pipeline: 2021.INTRODUCTION: The number of individuals worldwide with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") is growing at a rapid \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". New \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are urgently needed. We review the current pipeline of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trials\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". METHODS: We interrogated ClinicalTrials.gov, the federal registry of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trials\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to identify \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ": 28 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phase 3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " trials, 74 in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phase 2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", and 24 in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phase 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The majority of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in trials (82.5%) target the underlying biology of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " with the intent of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " modification; 10.3% are putative \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " enhancing agents; and 7.1% are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " being developed to reduce \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neuropsychiatric symptoms\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". DISCUSSION: This pipeline analysis shows that target biological \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    processes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    more\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " diversified, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    biomarkers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    more\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " regularly used, and repurposed agents are being explored to determine their utility for the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33730588</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " spontaneously self-assembles and recruits full-length \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation is a major pathological hallmark of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tauopathies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", but the mechanism(s) of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " remains unclear. Taking advantage of the identification of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filament\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cores\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " by cryoelectron microscopy, we demonstrate that the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " possesses the intrinsic ability to spontaneously aggregate in the absence of an inducer, with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    antibodies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " generated against \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " detecting \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " also drives \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of full-length wild-type \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", increases seeding potential, and templates abnormal forms of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " present in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " homogenates and antemortem \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cerebrospinal fluid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") from patients with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in an ultrasensitive real-time quaking-induced conversion (QuIC) \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assay\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Finally, we show that the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filament\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cores\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    corticobasal degeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (CBD) and Pick's \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (PiD) similarly assemble into \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " under physiological conditions. These results \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    document\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " an approach to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    modeling\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and have significant implications for in vivo investigation of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " transmission and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    biomarker\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " development.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# need to use docs, rather than docs_text \n",
    "displacy.render(docs, style=\"ent\", manual=True, options={\"colors\":{}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1a87ade8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "787cebe5",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5153eaab",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "366827db",
   "metadata": {},
   "source": [
    "### The second part for the PTC annotations\n",
    "- visusalize the PTC annotations removing the nested annotations in disPlacy\n",
    "- output the full PTC annotations (including the nested ones) in the json format"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "49a04e4b",
   "metadata": {},
   "outputs": [],
   "source": [
    "# goal: visualize the text span with the annotations by using spaCy visualizer\n",
    "# create the list of dictionaries as the input for spaCy visualizer\n",
    "# ex = [{\"text\": \"But Google is starting from behind.\",\n",
    "#        \"ents\": [{\"start\": 4, \"end\": 10, \"label\": \"ORG\"}],\n",
    "#        \"title\": \"Test\"}]\n",
    "# html = displacy.render(ex, style=\"ent\", manual=True, options={\"colors\":{\"ORG\":\"yellow\"}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "76f67d9c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# ptc annotations: \n",
    "# 34060233|t|[Title]\n",
    "# 34060233|a|[Abstract]\n",
    "# 34060233\t4\t8\tBIN1\tGene\t274\n",
    "# 34060233\t9\t17\trs744373\tSNP\trs744373"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "ad181036",
   "metadata": {},
   "outputs": [],
   "source": [
    "ptc_path = \"/Users/yidesdo21/Projects/ptc/Code.Python/output/\"\n",
    "ptc_file = \"ten_recent.PubTator\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "730d7580",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(ptc_path+ptc_file) as f:\n",
    "    ptc_output = f.read().splitlines()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "7d6e8a48",
   "metadata": {},
   "outputs": [],
   "source": [
    "ptc_outputs = list()  # turn one abstract into one list \n",
    "ptc_abs = list()\n",
    "\n",
    "for i in range(len(ptc_output)):\n",
    "    line = ptc_output[i]\n",
    "    ptc_abs.append(line)\n",
    "    \n",
    "    if len(line) == 0:    # start another article\n",
    "        ptc_outputs.append(ptc_abs)\n",
    "        ptc_abs = list()\n",
    "\n",
    "ptc_outputs = ptc_outputs[:-1]   # the last element is empty"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "75e9dbf9",
   "metadata": {},
   "source": [
    "#### create a map to link the identifiers to the ontological concepts — \n",
    "- genes/proteins → NCBI Gene identifiers, \n",
    "- Genetic variants → dbSNP RS identifiers, \n",
    "- Species → NCBI taxonomy identifiers, \n",
    "- Disease → MeSH identifiers, Chemicals → MeSH identifiers, \n",
    "- cell lines → Cellosaurus "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5d67eb3c",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "18a47b8c",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c585f273",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "204ab903",
   "metadata": {},
   "outputs": [],
   "source": [
    "# titles"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "d0d1622f",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# ptc_output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "577b9c2a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "ptc_docs = list()\n",
    "ptc_docs_text = list()  # for the json\n",
    "ptc_cnt = len(ptc_outputs)\n",
    "\n",
    "for i in range(ptc_cnt):   # iterate over each abstract \n",
    "    one_abs = ptc_outputs[i]\n",
    "    abs_dict = dict()\n",
    "    abs_dict_text = dict()  # for the json\n",
    "    text = \"\"\n",
    "    ents = list()\n",
    "    ents_text = list()  # for the json\n",
    "    \n",
    "    \n",
    "    for line in one_abs:   # iterate over each line in the abstract\n",
    "        line_split = line.split(\"|\")\n",
    "        if len(line_split) > 1:  # either the title line or the abstract line\n",
    "            abs_dict[\"title\"] = titles.get(line_split[0])\n",
    "            abs_dict_text[\"title\"] = titles.get(line_split[0])\n",
    "            \n",
    "#             print((line_split[0]))\n",
    "            \n",
    "            if line_split[1] == \"t\":\n",
    "                text += line_split[2]\n",
    "            elif line_split[1] == \"a\":\n",
    "                text += \".\"  # can't add a space because of the PTC annotations, the slicing will be wrong\n",
    "                text += line_split[2]\n",
    "                abs_dict[\"text\"] = text\n",
    "                abs_dict_text[\"text\"] = text\n",
    "    \n",
    "        span_split = line.split(\"\\t\")\n",
    "        ent = dict()\n",
    "        ent_text = dict()   # for the json\n",
    "        \n",
    "        if len(span_split) > 1:  # the text span lines \n",
    "            start, end, label = span_split[1], span_split[2], span_split[3]\n",
    "            ent[\"start\"] = int(start)\n",
    "            ent[\"end\"] = int(end)\n",
    "            ent[\"label\"] = span_split[4]  # for illustrations\n",
    "#             ent[\"label\"] = label\n",
    "            ents.append(ent)\n",
    "    \n",
    "            ent_text[\"span\"] = int(start), int(end)\n",
    "            ent_text[\"mention\"] = label\n",
    "\n",
    "#             print(span_split)\n",
    "            \n",
    "            if len(span_split) > 5:\n",
    "                ent_text[\"identifier\"] = span_split[5]    # the mention after grounding: ontological identifier\n",
    "            else:\n",
    "                ent_text[\"identifier\"] = \"none\"\n",
    "                \n",
    "            ent_text[\"concept\"] = \"\"         # not included in the PTC output, have to link to the ontologies\n",
    "            ent_text[\"type\"] = span_split[4]\n",
    "            ent_text[\"annotator\"] = \"PTC\"\n",
    "            ents_text.append(ent_text)  \n",
    "    \n",
    "        if len(line) == 0:  # end of this abstract\n",
    "            abs_dict[\"ents\"] = ents\n",
    "            ptc_docs.append(abs_dict)\n",
    "            abs_dict_text[\"ents\"] = ents_text\n",
    "            ptc_docs_text.append(abs_dict_text)\n",
    "            \n",
    "        \n",
    "        \n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "03a9ff33",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ptc_docs_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "a775efd4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'title': 'NLM_34060233',\n",
       "  'text': \"The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.INTRODUCTION: The BIN1 rs744373 single nucleotide polymorphism (SNP) is a key genetic risk locus for Alzheimer's disease (AD) associated with tau pathology. Because tau typically accumulates in response to amyloid beta (Aβ), we tested whether BIN1 rs744373 accelerates Aβ-related tau accumulation. METHODS: We included two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI], n\\xa0=\\xa0153; Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER], n\\xa0=\\xa063) with longitudinal (18) F-Flortaucipir positron emission tomography (PET), Aβ biomarkers, and longitudinal cognitive assessments. We assessed whether BIN1 rs744373 was associated with faster tau-PET accumulation at a given level of Aβ and whether faster BIN1 rs744373-associated tau-PET accumulation mediated cognitive decline. RESULTS: BIN1 rs744373 risk-allele carriers showed faster global tau-PET accumulation (ADNI/BioFINDER, P\\xa0<\\xa0.001/P\\xa0<\\xa0.001). We found significant Aβ by rs744373 interactions on global tau-PET change (ADNI: β/standard error [SE]\\xa0=\\xa00.42/0.14, P\\xa0=\\xa00.002; BioFINDER: β/SE\\xa0=\\xa0-0.35/0.15, P\\xa0=\\xa0.021), BIN1 risk-allele carriers showed accelerated tau-PET accumulation at higher Aβ levels. In ADNI, rs744373 effects on cognitive decline were mediated by faster global tau-PET accumulation (β/SE\\xa0=\\xa00.20/0.07, P\\xa0=\\xa0.005). DISCUSSION: BIN1-associated AD risk is potentially driven by accelerated tau accumulation in the face of Aβ.\",\n",
       "  'ents': [{'span': (4, 8),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (9, 17),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (18, 37),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (43, 46),\n",
       "    'mention': 'SNP',\n",
       "    'identifier': 'none',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (144, 148),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (149, 157),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (190, 193),\n",
       "    'mention': 'SNP',\n",
       "    'identifier': 'none',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (227, 246),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (248, 250),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (332, 339),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (369, 373),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (374, 382),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (546, 573),\n",
       "    'mention': 'Neurodegenerative Disorders',\n",
       "    'identifier': 'MESH:D019636',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (619, 631),\n",
       "    'mention': 'longitudinal',\n",
       "    'identifier': 'MESH:D017887',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (637, 660),\n",
       "    'mention': 'F-Flortaucipir positron',\n",
       "    'identifier': 'MESH:D005461',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (707, 729),\n",
       "    'mention': 'longitudinal cognitive',\n",
       "    'identifier': 'MESH:D003072',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (763, 767),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (768, 776),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (867, 871),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (872, 880),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (950, 954),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (955, 963),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1091, 1099),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1232, 1236),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1328, 1336),\n",
       "    'mention': 'rs744373',\n",
       "    'identifier': 'rs744373',\n",
       "    'concept': '',\n",
       "    'type': 'SNP',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1460, 1464),\n",
       "    'mention': 'BIN1',\n",
       "    'identifier': '274',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1476, 1478),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'NLM_34095440',\n",
       "  'text': \"Alzheimer's disease drug development pipeline: 2021.INTRODUCTION: The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. METHODS: We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. DISCUSSION: This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.\",\n",
       "  'ents': [{'span': (0, 19),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (107, 126),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (128, 130),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (276, 278),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (466, 468),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (610, 612),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (994, 996),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'NLM_34101788',\n",
       "  'text': \"Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for Alzheimer's disease (AD). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or participant groups; use uniform protocols and outcome measures; and may allow treatment arms to be added or dropped based on interim analyses of outcomes. The EU/US CTAD Task Force discussed the lessons learned from the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) platform trial and the challenges addressed by other platform trials that have launched or are in the planning stages. The landscape of clinical trial platforms in the AD space includes those testing experimental therapies such as DIAN-TU, platforms designed to test multidomain interventions, and those designed to streamline trial recruitment by building trial-ready cohorts. The heterogeneity of the AD patient population, AD drugs, treatment regimens, and analytical methods complicates the design and execution of platform trials, yet Task Force members concluded that platform trials are essential to advance the search for effective AD treatments, including combination therapies.\",\n",
       "  'ents': [{'span': (219, 238),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (240, 242),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (337, 348),\n",
       "    'mention': 'participant',\n",
       "    'identifier': '9606',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (578, 587),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (611, 618),\n",
       "    'mention': 'DIAN-TU',\n",
       "    'identifier': 'MESH:C559645',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (788, 790),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (851, 858),\n",
       "    'mention': 'DIAN-TU',\n",
       "    'identifier': 'MESH:C559645',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1023, 1025),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1026, 1033),\n",
       "    'mention': 'patient',\n",
       "    'identifier': '9606',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1046, 1048),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1260, 1262),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'NLM_33730588',\n",
       "  'text': \"The AD tau core spontaneously self-assembles and recruits full-length tau to filaments.Tau accumulation is a major pathological hallmark of Alzheimer's disease (AD) and other tauopathies, but the mechanism(s) of tau aggregation remains unclear. Taking advantage of the identification of tau filament cores by cryoelectron microscopy, we demonstrate that the AD tau core possesses the intrinsic ability to spontaneously aggregate in the absence of an inducer, with antibodies generated against AD tau core filaments detecting AD tau pathology. The AD tau core also drives aggregation of full-length wild-type tau, increases seeding potential, and templates abnormal forms of tau present in brain homogenates and antemortem cerebrospinal fluid (CSF) from patients with AD in an ultrasensitive real-time quaking-induced conversion (QuIC) assay. Finally, we show that the filament cores in corticobasal degeneration (CBD) and Pick's disease (PiD) similarly assemble into filaments under physiological conditions. These results document an approach to modeling tau aggregation and have significant implications for in\\xa0vivo investigation of tau transmission and biomarker development.\",\n",
       "  'ents': [{'span': (128, 159),\n",
       "    'mention': \"hallmark of Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (175, 186),\n",
       "    'mention': 'tauopathies',\n",
       "    'identifier': 'MESH:D024801',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (212, 227),\n",
       "    'mention': 'tau aggregation',\n",
       "    'identifier': 'MESH:C536599',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (753, 761),\n",
       "    'mention': 'patients',\n",
       "    'identifier': '9606',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (922, 936),\n",
       "    'mention': \"Pick's disease\",\n",
       "    'identifier': 'MESH:D020774',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1056, 1071),\n",
       "    'mention': 'tau aggregation',\n",
       "    'identifier': 'MESH:C536599',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'NLM_33988687',\n",
       "  'text': \"Alzheimer mutant speeds APP transport.APPS198P segregates with rare familial forms of Alzheimer's disease and resides within exon 5, unlike 27 other mutations that reside in exons 16 or 17. In this issue, Zhang et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210313) show that the brains of APPS198P transgenic mice accumulate excess levels of Aβ. In cultured cells, APPS198P undergoes accelerated ER folding, leading to early arrival in late vesicular compartments, thereby enhancing generation of Aβ.\",\n",
       "  'ents': [{'span': (0, 9),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (86, 105),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (308, 323),\n",
       "    'mention': 'transgenic mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'NLM_33958804',\n",
       "  'text': \"Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease.Selective neurodegeneration is a critical causal factor in Alzheimer's disease (AD); however, the mechanisms that lead some neurons to perish, whereas others remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-nucleus RNA sequencing and discovered that ApoE expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of ApoE-which has a robust genetic linkage to AD-correlated strongly, on a cell-by-cell basis, with immune response pathways in neurons in the brains of wild-type mice, human ApoE knock-in mice and humans with or without AD. Elimination or over-expression of neuronal ApoE revealed a causal relationship among ApoE expression, neuronal MHC-I expression, tau pathology and neurodegeneration. Functional reduction of MHC-I ameliorated tau pathology in ApoE4-expressing primary neurons and in mouse hippocampi expressing pathological tau. These findings suggest a mechanism linking neuronal ApoE expression to MHC-I expression and, subsequently, to tau pathology and selective neurodegeneration.\",\n",
       "  'ents': [{'span': (9, 13),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '11816',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (62, 79),\n",
       "    'mention': 'neurodegeneration',\n",
       "    'identifier': 'MESH:D019636',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (83, 102),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (113, 130),\n",
       "    'mention': 'neurodegeneration',\n",
       "    'identifier': 'MESH:D019636',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (162, 181),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (183, 185),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (408, 412),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '11816',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (514, 518),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '11816',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (557, 559),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (674, 678),\n",
       "    'mention': 'mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (680, 685),\n",
       "    'mention': 'human',\n",
       "    'identifier': '9606',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (686, 690),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '348',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (700, 704),\n",
       "    'mention': 'mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (709, 715),\n",
       "    'mention': 'humans',\n",
       "    'identifier': '9606',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (732, 734),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (779, 783),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '348',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (821, 825),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '348',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (883, 900),\n",
       "    'mention': 'neurodegeneration',\n",
       "    'identifier': 'MESH:D019636',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1001, 1006),\n",
       "    'mention': 'mouse',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1099, 1103),\n",
       "    'mention': 'ApoE',\n",
       "    'identifier': '11816',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1185, 1202),\n",
       "    'mention': 'neurodegeneration',\n",
       "    'identifier': 'MESH:D019636',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'NLM_31721178',\n",
       "  'text': \"Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brain.The constituent paired helical filaments (PHFs) in neurofibrillary tangles are insoluble intracellular deposits central to the development of Alzheimer's disease (AD) and other tauopathies. Full-length tau requires the addition of anionic cofactors such as heparin to enhance assembly. We have shown that a fragment from the proteolytically stable core of the PHF, tau 297-391 known as 'dGAE', spontaneously forms cross-β-containing PHFs and straight filaments under physiological conditions. Here, we have analysed and compared the structures of the filaments formed by dGAE in\\xa0vitro with those deposited in the brains of individuals diagnosed with AD. We show that dGAE forms PHFs that share a macromolecular structure similar to those found in brain tissue. Thus, dGAEs may serve as a model system for studying core domain assembly and for screening for inhibitors of tau aggregation.\",\n",
       "  'ents': [{'span': (94, 113),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (262, 281),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (283, 285),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (297, 308),\n",
       "    'mention': 'tauopathies',\n",
       "    'identifier': 'MESH:D024801',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (377, 384),\n",
       "    'mention': 'heparin',\n",
       "    'identifier': 'MESH:D006493',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (770, 772),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (991, 1006),\n",
       "    'mention': 'tau aggregation',\n",
       "    'identifier': 'MESH:C536599',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'CCC_000637925000033',\n",
       "  'text': 'Glycoengineering artificial receptors for microglia to phagocytose A beta aggregates.Oligomeric and fibrillar amyloid-beta (A beta) are principally internalized via receptor-mediated endocytosis (RME) by microglia, the main scavenger of A beta in the brain. Nevertheless, the inflammatory cascade will be evoked after vast A beta aggregate binding to pattern recognition receptors on the cell membrane, which then significantly decreases the expression of these receptors and further deteriorate A beta deposition. This vicious circle will weaken the ability of microglia for A beta elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial membranes with ThS as artificial A beta receptors to promote microglia to phagocytose A beta aggregates. Additionally, to circumvent the undesirable immune response during the process of the bioorthogonal chemistry reaction and A beta-microglial interaction, Mn-porphyrin metal-organic frameworks (Mn-MOFs) with superoxide dismutase (SOD) and catalase (CAT) mimic activity are employed to carry N-azidoacetylmannosamine (AcManNAz) and eradicate over-expressed reactive oxygen species (ROSs). The artificial A beta receptors independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with antioxidant properties can synergistically promote the phagocytosis and clearance of A beta with significantly enhanced activity and negligible adverse effects. The present study will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for other disease intervention associated with receptor starvation.',\n",
       "  'ents': [{'span': (67, 73),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (110, 122),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (124, 130),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (196, 199),\n",
       "    'mention': 'RME',\n",
       "    'identifier': 'none',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (237, 243),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (323, 329),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (496, 502),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (576, 582),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (751, 757),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (804, 810),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (946, 952),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (977, 989),\n",
       "    'mention': 'Mn-porphyrin',\n",
       "    'identifier': 'MESH:D008345',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1016, 1023),\n",
       "    'mention': 'Mn-MOFs',\n",
       "    'identifier': 'MESH:D008345',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1030, 1050),\n",
       "    'mention': 'superoxide dismutase',\n",
       "    'identifier': '6647',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1052, 1055),\n",
       "    'mention': 'SOD',\n",
       "    'identifier': '6647',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1061, 1069),\n",
       "    'mention': 'catalase',\n",
       "    'identifier': '847',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1071, 1074),\n",
       "    'mention': 'CAT',\n",
       "    'identifier': '847',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1113, 1137),\n",
       "    'mention': 'N-azidoacetylmannosamine',\n",
       "    'identifier': 'MESH:C405953',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1187, 1193),\n",
       "    'mention': 'oxygen',\n",
       "    'identifier': 'MESH:D010100',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1225, 1231),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1412, 1418),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'CCC_000647663200001',\n",
       "  'text': 'Impairment of visual cortical plasticity by amyloid-beta species.Introduction: A variety of transgenic and knock-in mice that express mutant alleles of Amyloid precursor protein (APP) have been used to model the effects of amyloid-beta (A?) on circuit function in Alzheimer?s disease (AD); however phenotypes described in these mice may be affected by expression of mutant APP or proteolytic cleavage products independent of A?. In addition, the effects of mutant APP expression are attributed to elevated expression of the amyloidogenic, 42-amino acid-long species of A? (A?42) associated with amyloid plaque accumulation in AD, though elevated concentrations of A?40, an A? species produced with normal synaptic activity, may also affect neural function. Methods: To explore the effects of elevated expression of A? on synaptic function in vivo, we assessed visual system plasticity in transgenic mice that express and secrete A? throughout the brain in the absence of APP overexpression. Transgenic mice that express either A?40 or A?42 were assayed for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation. Results: Using two complementary approaches to measure the plastic response to monocular deprivation, we find that male and female mice that express either 40- or 42-amino acid?long A? species demonstrate a plasticity defect comparable to that elicited in transgenic mice that express mutant alleles of APP and Presenilin 1 (APP/PS1 mice). Conclusions: These data support the hypothesis that mutant APP-driven plasticity impairment in mouse models of AD is mediated by production and accumulation of A?. Moreover, these findings suggest that soluble species of A? are capable of modulating synaptic plasticity, likely independent of any aggregation. These findings may have implications for the role of soluble species of A? in both development and disease settings.',\n",
       "  'ents': [{'span': (0, 40),\n",
       "    'mention': 'Impairment of visual cortical plasticity',\n",
       "    'identifier': 'MESH:D014786',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (44, 51),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (116, 120),\n",
       "    'mention': 'mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (152, 177),\n",
       "    'mention': 'Amyloid precursor protein',\n",
       "    'identifier': '11820',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (223, 235),\n",
       "    'mention': 'amyloid-beta',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (264, 273),\n",
       "    'mention': 'Alzheimer',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (274, 283),\n",
       "    'mention': 's disease',\n",
       "    'identifier': 'MESH:D010300',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (285, 287),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (328, 332),\n",
       "    'mention': 'mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (524, 537),\n",
       "    'mention': 'amyloidogenic',\n",
       "    'identifier': 'MESH:C468911',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (539, 552),\n",
       "    'mention': '42-amino acid',\n",
       "    'identifier': 'MESH:C011973',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (595, 602),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (626, 628),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (888, 903),\n",
       "    'mention': 'transgenic mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (991, 1006),\n",
       "    'mention': 'Transgenic mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1292, 1296),\n",
       "    'mention': 'mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1324, 1337),\n",
       "    'mention': '42-amino acid',\n",
       "    'identifier': 'MESH:C011973',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1417, 1432),\n",
       "    'mention': 'transgenic mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1472, 1484),\n",
       "    'mention': 'Presenilin 1',\n",
       "    'identifier': '19164',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1490, 1493),\n",
       "    'mention': 'PS1',\n",
       "    'identifier': '19164',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1494, 1498),\n",
       "    'mention': 'mice',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1596, 1601),\n",
       "    'mention': 'mouse',\n",
       "    'identifier': '10090',\n",
       "    'concept': '',\n",
       "    'type': 'Species',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1612, 1614),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]},\n",
       " {'title': 'CCC_000653155500009',\n",
       "  'text': \"An excellent electrochemical aptasensor for amyloid-beta oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events.An excellent aptasensor for electrochemical detection of amyloid-beta oligomers (A beta Os) at trace levels was fabricated based on a triple-helix aptamer switch (THAS) via target-triggered signal transduction DNA displacement events. Specifically, a single-stranded anti-A beta O aptamer (Apt) carrying two symmetrical arm segments was first attached via Au-S binding to an Au electrode. Gold nanoparticle (GNP)-tagged signal transduction probes (GNP-STPs) were simultaneously hybridized with the two arm segments of the Apt, and a rigid THAS was formed on the Au electrode. Compared to the conventional hybrid, the number of GNPs on the Au electrode increased significantly with the THAS, effectively improving the stability of the Apt to avoid lodging. Trithiocyanuric acid (TA) was utilized to further gather the GNPs and form network-like TA/GNPs. As a result, the differential pulse voltammetry (DPV) response of GNPs was clearly enhanced. When A beta Os were present, target-triggered signal transduction DNA displacement events were carried out from THAS via the reaction of the Apt with the A beta Os, which caused the GNP-STP to dissociate from the Au electrode, and thus a significant reduction in the DPV response was observed. The assay was able to sensitively detect trace A beta Os by monitoring the A beta O-controlled DPV response change. It exhibited a wide linear range from 1 fM to 10 pM with a low detection limit of 0.5 fM, and was successfully employed for the determination of A beta Os in 20 serum samples, with good recovery. Moreover, the developed assay can provide a sensitive and selective platform for many studies or investigations related to Alzheimer's disease (AD) monitoring and treatment.\",\n",
       "  'ents': [{'span': (44, 51),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (228, 235),\n",
       "    'mention': 'amyloid',\n",
       "    'identifier': 'MESH:D016229',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (927, 947),\n",
       "    'mention': 'Trithiocyanuric acid',\n",
       "    'identifier': 'MESH:C039408',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (949, 951),\n",
       "    'mention': 'TA',\n",
       "    'identifier': 'MESH:C011126',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1015, 1017),\n",
       "    'mention': 'TA',\n",
       "    'identifier': 'MESH:C011126',\n",
       "    'concept': '',\n",
       "    'type': 'Chemical',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1122, 1128),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1271, 1277),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1458, 1464),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1486, 1492),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1672, 1678),\n",
       "    'mention': 'A beta',\n",
       "    'identifier': '351',\n",
       "    'concept': '',\n",
       "    'type': 'Gene',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1846, 1865),\n",
       "    'mention': \"Alzheimer's disease\",\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'},\n",
       "   {'span': (1867, 1869),\n",
       "    'mention': 'AD',\n",
       "    'identifier': 'MESH:D000544',\n",
       "    'concept': '',\n",
       "    'type': 'Disease',\n",
       "    'annotator': 'PTC'}]}]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ptc_docs_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "dbb73d7d",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ptc_docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "0c92e900",
   "metadata": {},
   "outputs": [],
   "source": [
    "write_to_json(result_path, ptc_docs_text, output_file.replace(\"nio\",\"ptc\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "9dc320ff",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'ptc_ten_recent_spans_nested_case.txt'"
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_file.replace(\"nio\",\"ptc\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f3ad9c88",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "id": "00bd9f61",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><h2 style=\"margin: 0\">NLM_34060233</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " risk \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SNP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " is associated with faster Aβ-associated tau accumulation and cognitive decline.INTRODUCTION: The \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " single nucleotide polymorphism (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SNP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") is a key genetic risk locus for \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") associated with tau pathology. Because tau typically accumulates in response to \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " beta (Aβ), we tested whether \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " accelerates Aβ-related tau accumulation. METHODS: We included two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI], n = 153; Biomarkers for Identifying \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Neurodegenerative Disorders\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " Early and Reliably [BioFINDER], n = 63) with \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    longitudinal\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (18) \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F-Flortaucipir positron\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " emission tomography (PET), Aβ biomarkers, and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    longitudinal cognitive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " assessments. We assessed whether \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " was associated with faster tau-PET accumulation at a given level of Aβ and whether faster \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       "-associated tau-PET accumulation mediated cognitive decline. RESULTS: \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " risk-allele carriers showed faster global tau-PET accumulation (ADNI/BioFINDER, P &lt; .001/P &lt; .001). We found significant Aβ by \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " interactions on global tau-PET change (ADNI: β/standard error [SE] = 0.42/0.14, P = 0.002; BioFINDER: β/SE = -0.35/0.15, P = .021), \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " risk-allele carriers showed accelerated tau-PET accumulation at higher Aβ levels. In ADNI, \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " effects on cognitive decline were mediated by faster global tau-PET accumulation (β/SE = 0.20/0.07, P = .005). DISCUSSION: \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       "-associated \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " risk is potentially driven by accelerated tau accumulation in the face of Aβ.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34095440</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " drug development pipeline: 2021.INTRODUCTION: The number of individuals worldwide with \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". METHODS: We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ": 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. DISCUSSION: This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34101788</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    participant\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " groups; use uniform protocols and outcome measures; and may allow treatment arms to be added or dropped based on interim analyses of outcomes. The EU/US CTAD Task Force discussed the lessons learned from the Dominantly Inherited \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "'s Network Trials Unit (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DIAN-TU\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") platform trial and the challenges addressed by other platform trials that have launched or are in the planning stages. The landscape of clinical trial platforms in the \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " space includes those testing experimental therapies such as \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DIAN-TU\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ", platforms designed to test multidomain interventions, and those designed to streamline trial recruitment by building trial-ready cohorts. The heterogeneity of the \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    patient\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " population, \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " drugs, treatment regimens, and analytical methods complicates the design and execution of platform trials, yet Task Force members concluded that platform trials are essential to advance the search for effective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " treatments, including combination therapies.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33730588</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The AD tau core spontaneously self-assembles and recruits full-length tau to filaments.Tau accumulation is a major pathological \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hallmark of Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (AD) and other \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tauopathies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ", but the mechanism(s) of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " remains unclear. Taking advantage of the identification of tau filament cores by cryoelectron microscopy, we demonstrate that the AD tau core possesses the intrinsic ability to spontaneously aggregate in the absence of an inducer, with antibodies generated against AD tau core filaments detecting AD tau pathology. The AD tau core also drives aggregation of full-length wild-type tau, increases seeding potential, and templates abnormal forms of tau present in brain homogenates and antemortem cerebrospinal fluid (CSF) from \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    patients\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " with AD in an ultrasensitive real-time quaking-induced conversion (QuIC) assay. Finally, we show that the filament cores in corticobasal degeneration (CBD) and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pick's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (PiD) similarly assemble into filaments under physiological conditions. These results document an approach to modeling \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " and have significant implications for in vivo investigation of tau transmission and biomarker development.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33988687</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " mutant speeds APP transport.APPS198P segregates with rare familial forms of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " and resides within exon 5, unlike 27 other mutations that reside in exons 16 or 17. In this issue, Zhang et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210313) show that the brains of APPS198P \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " accumulate excess levels of Aβ. In cultured cells, APPS198P undergoes accelerated ER folding, leading to early arrival in late vesicular compartments, thereby enhancing generation of Aβ.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33958804</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Neuronal \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " upregulates MHC-I expression to drive selective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".Selective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " is a critical causal factor in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "); however, the mechanisms that lead some neurons to perish, whereas others remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-nucleus RNA sequencing and discovered that \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       "-which has a robust genetic linkage to \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "-correlated strongly, on a cell-by-cell basis, with immune response pathways in neurons in the brains of wild-type \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    human\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " knock-in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    humans\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " with or without \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Elimination or over-expression of neuronal \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " revealed a causal relationship among \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " expression, neuronal MHC-I expression, tau pathology and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Functional reduction of MHC-I ameliorated tau pathology in ApoE4-expressing primary neurons and in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " hippocampi expressing pathological tau. These findings suggest a mechanism linking neuronal \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " expression to MHC-I expression and, subsequently, to tau pathology and selective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_31721178</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " brain.The constituent paired helical filaments (PHFs) in neurofibrillary tangles are insoluble intracellular deposits central to the development of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") and other \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tauopathies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Full-length tau requires the addition of anionic cofactors such as \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heparin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " to enhance assembly. We have shown that a fragment from the proteolytically stable core of the PHF, tau 297-391 known as 'dGAE', spontaneously forms cross-β-containing PHFs and straight filaments under physiological conditions. Here, we have analysed and compared the structures of the filaments formed by dGAE in vitro with those deposited in the brains of individuals diagnosed with \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". We show that dGAE forms PHFs that share a macromolecular structure similar to those found in brain tissue. Thus, dGAEs may serve as a model system for studying core domain assembly and for screening for inhibitors of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000637925000033</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Glycoengineering artificial receptors for microglia to phagocytose \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " aggregates.Oligomeric and fibrillar \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       ") are principally internalized via receptor-mediated endocytosis (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RME\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") by microglia, the main scavenger of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " in the brain. Nevertheless, the inflammatory cascade will be evoked after vast \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " aggregate binding to pattern recognition receptors on the cell membrane, which then significantly decreases the expression of these receptors and further deteriorate \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " deposition. This vicious circle will weaken the ability of microglia for \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial membranes with ThS as artificial \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " receptors to promote microglia to phagocytose \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " aggregates. Additionally, to circumvent the undesirable immune response during the process of the bioorthogonal chemistry reaction and \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       "-microglial interaction, \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mn-porphyrin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " metal-organic frameworks (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mn-MOFs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") with \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    superoxide dismutase\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SOD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalase\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CAT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       ") mimic activity are employed to carry \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    N-azidoacetylmannosamine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (AcManNAz) and eradicate over-expressed reactive \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxygen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " species (ROSs). The artificial \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " receptors independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with antioxidant properties can synergistically promote the phagocytosis and clearance of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " with significantly enhanced activity and negligible adverse effects. The present study will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for other disease intervention associated with receptor starvation.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000647663200001</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Impairment of visual cortical plasticity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " by \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "-beta species.Introduction: A variety of transgenic and knock-in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express mutant alleles of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amyloid precursor protein\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (APP) have been used to model the effects of \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (A?) on circuit function in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "?\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "); however phenotypes described in these \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " may be affected by expression of mutant APP or proteolytic cleavage products independent of A?. In addition, the effects of mutant APP expression are attributed to elevated expression of the \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloidogenic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    42-amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "-long species of A? (A?42) associated with \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " plaque accumulation in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ", though elevated concentrations of A?40, an A? species produced with normal synaptic activity, may also affect neural function. Methods: To explore the effects of elevated expression of A? on synaptic function in vivo, we assessed visual system plasticity in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express and secrete A? throughout the brain in the absence of APP overexpression. \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express either A?40 or A?42 were assayed for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation. Results: Using two complementary approaches to measure the plastic response to monocular deprivation, we find that male and female \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express either 40- or \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    42-amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "?long A? species demonstrate a plasticity defect comparable to that elicited in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express mutant alleles of APP and \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Presenilin 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (APP/\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PS1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "). Conclusions: These data support the hypothesis that mutant APP-driven plasticity impairment in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " models of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " is mediated by production and accumulation of A?. Moreover, these findings suggest that soluble species of A? are capable of modulating synaptic plasticity, likely independent of any aggregation. These findings may have implications for the role of soluble species of A? in both development and disease settings.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000653155500009</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">An excellent electrochemical aptasensor for \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "-beta oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events.An excellent aptasensor for electrochemical detection of \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "-beta oligomers (A beta Os) at trace levels was fabricated based on a triple-helix aptamer switch (THAS) via target-triggered signal transduction DNA displacement events. Specifically, a single-stranded anti-A beta O aptamer (Apt) carrying two symmetrical arm segments was first attached via Au-S binding to an Au electrode. Gold nanoparticle (GNP)-tagged signal transduction probes (GNP-STPs) were simultaneously hybridized with the two arm segments of the Apt, and a rigid THAS was formed on the Au electrode. Compared to the conventional hybrid, the number of GNPs on the Au electrode increased significantly with the THAS, effectively improving the stability of the Apt to avoid lodging. \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Trithiocyanuric acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") was utilized to further gather the GNPs and form network-like \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "/GNPs. As a result, the differential pulse voltammetry (DPV) response of GNPs was clearly enhanced. When \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os were present, target-triggered signal transduction DNA displacement events were carried out from THAS via the reaction of the Apt with the \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os, which caused the GNP-STP to dissociate from the Au electrode, and thus a significant reduction in the DPV response was observed. The assay was able to sensitively detect trace \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os by monitoring the \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " O-controlled DPV response change. It exhibited a wide linear range from 1 fM to 10 pM with a low detection limit of 0.5 fM, and was successfully employed for the determination of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os in 20 serum samples, with good recovery. Moreover, the developed assay can provide a sensitive and selective platform for many studies or investigations related to \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") monitoring and treatment.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(ptc_docs, style=\"ent\", manual=True, \n",
    "                options={\"colors\":{\"GENE\":\"aqua\", \"DISEASE\":\"pink\", \"CHEMICAL\":\"violet\",\n",
    "                                   \"SNP\":\"moccasin\", \"SPECIES\":\"lightgreen\"}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c359b791",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d9771fc8",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f4c247fe",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cf3a105c",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "175a35f6",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "fe6b4be0",
   "metadata": {},
   "source": [
    "### combine the annotation spans from NIO and PTC\n",
    "- leave the duplications there\n",
    "- filtering duplications: when the text spans are the same, the grounding will be the PTC's. We are not removing the duplications for the same starting index but different ending indices. We are not removing the duplications for the mentions with different grounded results (different identifiers or different ontological concepts). "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "389cf65e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dd12e595",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ac3e928e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "12fa9c36",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "15a0c425",
   "metadata": {},
   "source": [
    "#### the combined annotations without filtering duplications"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "2926fb79",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# NIO annotations - docs_text\n",
    "# PTC annotations - ptc_docs_text\n",
    "\n",
    "a = defaultdict(list) \n",
    "\n",
    "for elem in ptc_docs_text:\n",
    "    a[(elem['title'],elem['text'])].extend(elem['ents'])\n",
    "\n",
    "for elem in docs_text:\n",
    "    a[(elem['title'],elem['text'])].extend(elem['ents'])\n",
    "\n",
    "Output = [{\"title\":x[0], 'text':x[1], \"ents\": sorted(y, key=lambda x: x['span'])} for x, y in a.items()]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "7b2e2e24",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(Output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "51968477",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'title': 'NLM_34060233',\n",
       " 'text': \"The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.INTRODUCTION: The BIN1 rs744373 single nucleotide polymorphism (SNP) is a key genetic risk locus for Alzheimer's disease (AD) associated with tau pathology. Because tau typically accumulates in response to amyloid beta (Aβ), we tested whether BIN1 rs744373 accelerates Aβ-related tau accumulation. METHODS: We included two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI], n\\xa0=\\xa0153; Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER], n\\xa0=\\xa063) with longitudinal (18) F-Flortaucipir positron emission tomography (PET), Aβ biomarkers, and longitudinal cognitive assessments. We assessed whether BIN1 rs744373 was associated with faster tau-PET accumulation at a given level of Aβ and whether faster BIN1 rs744373-associated tau-PET accumulation mediated cognitive decline. RESULTS: BIN1 rs744373 risk-allele carriers showed faster global tau-PET accumulation (ADNI/BioFINDER, P\\xa0<\\xa0.001/P\\xa0<\\xa0.001). We found significant Aβ by rs744373 interactions on global tau-PET change (ADNI: β/standard error [SE]\\xa0=\\xa00.42/0.14, P\\xa0=\\xa00.002; BioFINDER: β/SE\\xa0=\\xa0-0.35/0.15, P\\xa0=\\xa0.021), BIN1 risk-allele carriers showed accelerated tau-PET accumulation at higher Aβ levels. In ADNI, rs744373 effects on cognitive decline were mediated by faster global tau-PET accumulation (β/SE\\xa0=\\xa00.20/0.07, P\\xa0=\\xa0.005). DISCUSSION: BIN1-associated AD risk is potentially driven by accelerated tau accumulation in the face of Aβ.\",\n",
       " 'ents': [{'span': (4, 8),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (4, 8),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (9, 17),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (18, 27),\n",
       "   'mention': 'Alzheimer',\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (18, 29),\n",
       "   'mention': \"Alzheimer's\",\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (18, 37),\n",
       "   'mention': \"Alzheimer's disease\",\n",
       "   'identifier': 'MESH:D000544',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (18, 37),\n",
       "   'mention': \"Alzheimer's disease\",\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (30, 37),\n",
       "   'mention': 'disease',\n",
       "   'identifier': 'obo:OGMS_0000031',\n",
       "   'concept': 'disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (30, 37),\n",
       "   'mention': 'disease',\n",
       "   'identifier': 'NDDUO:disease',\n",
       "   'concept': 'disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (38, 42),\n",
       "   'mention': 'risk',\n",
       "   'identifier': 'NDDUO:Risk_factor',\n",
       "   'concept': 'Risk factor',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (43, 46),\n",
       "   'mention': 'SNP',\n",
       "   'identifier': 'none',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (87, 90),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (108, 117),\n",
       "   'mention': 'cognitive',\n",
       "   'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "   'concept': 'Cognitive Test',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (108, 125),\n",
       "   'mention': 'cognitive decline',\n",
       "   'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline',\n",
       "   'concept': 'Moderate cognitive Decline',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (108, 125),\n",
       "   'mention': 'cognitive decline',\n",
       "   'identifier': 'AlzheimerOntology:mental_disorder',\n",
       "   'concept': 'mental disorder',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (144, 148),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (144, 148),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (149, 157),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (190, 193),\n",
       "   'mention': 'SNP',\n",
       "   'identifier': 'none',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (212, 216),\n",
       "   'mention': 'risk',\n",
       "   'identifier': 'NDDUO:Risk_factor',\n",
       "   'concept': 'Risk factor',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (227, 236),\n",
       "   'mention': 'Alzheimer',\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (227, 238),\n",
       "   'mention': \"Alzheimer's\",\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (227, 246),\n",
       "   'mention': \"Alzheimer's disease\",\n",
       "   'identifier': 'MESH:D000544',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (227, 246),\n",
       "   'mention': \"Alzheimer's disease\",\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (239, 246),\n",
       "   'mention': 'disease',\n",
       "   'identifier': 'obo:OGMS_0000031',\n",
       "   'concept': 'disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (239, 246),\n",
       "   'mention': 'disease',\n",
       "   'identifier': 'NDDUO:disease',\n",
       "   'concept': 'disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (248, 250),\n",
       "   'mention': 'AD',\n",
       "   'identifier': 'MESH:D000544',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (248, 250),\n",
       "   'mention': 'AD',\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (268, 271),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (268, 281),\n",
       "   'mention': 'tau pathology',\n",
       "   'identifier': 'AlzheimerOntology:tauopathy',\n",
       "   'concept': 'tauopathy',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (291, 294),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (332, 339),\n",
       "   'mention': 'amyloid',\n",
       "   'identifier': 'MESH:D016229',\n",
       "   'concept': '',\n",
       "   'type': 'Chemical',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (332, 339),\n",
       "   'mention': 'amyloid',\n",
       "   'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "   'concept': 'amyloid beta protein',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (332, 344),\n",
       "   'mention': 'amyloid beta',\n",
       "   'identifier': 'AlzheimerOntology:amyloid_beta_protein',\n",
       "   'concept': 'amyloid beta protein',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (369, 373),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (369, 373),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (374, 382),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (406, 409),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (449, 456),\n",
       "   'mention': 'samples',\n",
       "   'identifier': 'NDDUO:Sampling',\n",
       "   'concept': 'Sampling',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (458, 467),\n",
       "   'mention': 'Alzheimer',\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (458, 469),\n",
       "   'mention': \"Alzheimer's\",\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (458, 477),\n",
       "   'mention': \"Alzheimer's Disease\",\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (458, 501),\n",
       "   'mention': \"Alzheimer's Disease Neuroimaging Initiative\",\n",
       "   'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "   'concept': 'neuroimaging',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (470, 477),\n",
       "   'mention': 'Disease',\n",
       "   'identifier': 'obo:OGMS_0000031',\n",
       "   'concept': 'disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (470, 477),\n",
       "   'mention': 'Disease',\n",
       "   'identifier': 'NDDUO:disease',\n",
       "   'concept': 'disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (478, 490),\n",
       "   'mention': 'Neuroimaging',\n",
       "   'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "   'concept': 'neuroimaging',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (503, 507),\n",
       "   'mention': 'ADNI',\n",
       "   'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "   'concept': 'neuroimaging',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (519, 529),\n",
       "   'mention': 'Biomarkers',\n",
       "   'identifier': 'AlzheimerOntology:procedures_using_biomarkers',\n",
       "   'concept': 'thing related to procedure using biomarkers',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (519, 529),\n",
       "   'mention': 'Biomarkers',\n",
       "   'identifier': 'NDDUO:biomarker',\n",
       "   'concept': 'biomarker',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (546, 573),\n",
       "   'mention': 'Neurodegenerative Disorders',\n",
       "   'identifier': 'MESH:D019636',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (546, 573),\n",
       "   'mention': 'Neurodegenerative Disorders',\n",
       "   'identifier': 'NDDUO:disorder',\n",
       "   'concept': 'disorder',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (546, 573),\n",
       "   'mention': 'Neurodegenerative Disorders',\n",
       "   'identifier': 'NDDUO:neurodegenerative_disease',\n",
       "   'concept': 'neurodegenerative disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (564, 573),\n",
       "   'mention': 'Disorders',\n",
       "   'identifier': 'NDDUO:disorder',\n",
       "   'concept': 'disorder',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (619, 631),\n",
       "   'mention': 'longitudinal',\n",
       "   'identifier': 'MESH:D017887',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (637, 660),\n",
       "   'mention': 'F-Flortaucipir positron',\n",
       "   'identifier': 'MESH:D005461',\n",
       "   'concept': '',\n",
       "   'type': 'Chemical',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (652, 680),\n",
       "   'mention': 'positron emission tomography',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (682, 685),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (691, 701),\n",
       "   'mention': 'biomarkers',\n",
       "   'identifier': 'AlzheimerOntology:procedures_using_biomarkers',\n",
       "   'concept': 'thing related to procedure using biomarkers',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (691, 701),\n",
       "   'mention': 'biomarkers',\n",
       "   'identifier': 'NDDUO:biomarker',\n",
       "   'concept': 'biomarker',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (707, 729),\n",
       "   'mention': 'longitudinal cognitive',\n",
       "   'identifier': 'MESH:D003072',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (720, 729),\n",
       "   'mention': 'cognitive',\n",
       "   'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "   'concept': 'Cognitive Test',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (763, 767),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (763, 767),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (768, 776),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (804, 807),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (808, 811),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (867, 871),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (867, 871),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (872, 880),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (892, 895),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (896, 899),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (922, 931),\n",
       "   'mention': 'cognitive',\n",
       "   'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "   'concept': 'Cognitive Test',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (922, 939),\n",
       "   'mention': 'cognitive decline',\n",
       "   'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline',\n",
       "   'concept': 'Moderate cognitive Decline',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (922, 939),\n",
       "   'mention': 'cognitive decline',\n",
       "   'identifier': 'AlzheimerOntology:mental_disorder',\n",
       "   'concept': 'mental disorder',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (950, 954),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (950, 954),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (955, 963),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (964, 968),\n",
       "   'mention': 'risk',\n",
       "   'identifier': 'NDDUO:Risk_factor',\n",
       "   'concept': 'Risk factor',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1006, 1009),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1010, 1013),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1028, 1032),\n",
       "   'mention': 'ADNI',\n",
       "   'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "   'concept': 'neuroimaging',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1091, 1099),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (1123, 1126),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1127, 1130),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1139, 1143),\n",
       "   'mention': 'ADNI',\n",
       "   'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "   'concept': 'neuroimaging',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1232, 1236),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (1232, 1236),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1237, 1241),\n",
       "   'mention': 'risk',\n",
       "   'identifier': 'NDDUO:Risk_factor',\n",
       "   'concept': 'Risk factor',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1277, 1280),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1281, 1284),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1322, 1326),\n",
       "   'mention': 'ADNI',\n",
       "   'identifier': 'AlzheimerOntology:neuroimaging',\n",
       "   'concept': 'neuroimaging',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1328, 1336),\n",
       "   'mention': 'rs744373',\n",
       "   'identifier': 'rs744373',\n",
       "   'concept': '',\n",
       "   'type': 'SNP',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (1348, 1357),\n",
       "   'mention': 'cognitive',\n",
       "   'identifier': 'AlzheimerOntology:Cognitive_Tests',\n",
       "   'concept': 'Cognitive Test',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1348, 1365),\n",
       "   'mention': 'cognitive decline',\n",
       "   'identifier': 'AlzheimerOntology:Moderate_cognitive_Decline',\n",
       "   'concept': 'Moderate cognitive Decline',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1348, 1365),\n",
       "   'mention': 'cognitive decline',\n",
       "   'identifier': 'AlzheimerOntology:mental_disorder',\n",
       "   'concept': 'mental disorder',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1397, 1400),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1401, 1404),\n",
       "   'mention': 'PET',\n",
       "   'identifier': 'AlzheimerOntology:Positron_emission_tomography',\n",
       "   'concept': 'Positron emission tomography',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1460, 1464),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': '274',\n",
       "   'concept': '',\n",
       "   'type': 'Gene',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (1460, 1464),\n",
       "   'mention': 'BIN1',\n",
       "   'identifier': 'AlzheimerOntology:BIN1',\n",
       "   'concept': 'BIN1',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1476, 1478),\n",
       "   'mention': 'AD',\n",
       "   'identifier': 'MESH:D000544',\n",
       "   'concept': '',\n",
       "   'type': 'Disease',\n",
       "   'annotator': 'PTC'},\n",
       "  {'span': (1476, 1478),\n",
       "   'mention': 'AD',\n",
       "   'identifier': 'AlzheimerOntology:Subtypes',\n",
       "   'concept': 'Alzheimer disease',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1479, 1483),\n",
       "   'mention': 'risk',\n",
       "   'identifier': 'NDDUO:Risk_factor',\n",
       "   'concept': 'Risk factor',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'},\n",
       "  {'span': (1521, 1524),\n",
       "   'mention': 'tau',\n",
       "   'identifier': 'AlzheimerOntology:t_tau',\n",
       "   'concept': 't-tau',\n",
       "   'type': '',\n",
       "   'annotator': 'NIO'}]}"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Output[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "5898abd4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/Users/yidesdo21/Projects/outputs/10_ptc_ten_recent/json/'"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result_path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "99ddc1be",
   "metadata": {},
   "outputs": [],
   "source": [
    "write_to_json(result_path, Output, output_file.replace(\"nio\",\"combined\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7cecf3b0",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "01e03a85",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "549f4942",
   "metadata": {},
   "source": [
    "#### the combined annotations after filtering duplications"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "f89d4da2",
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "filtered_output = list()\n",
    "\n",
    "for i in Output:\n",
    "    filtered_dict = dict()\n",
    "    ents = i[\"ents\"]\n",
    "    filtered_ents = list()\n",
    "    start_end_set = set()\n",
    "    filtered_dict[\"title\"], filtered_dict[\"text\"] = i[\"title\"],i[\"text\"]\n",
    "    \n",
    "    for ent in ents:\n",
    "        start,end,label = ent[\"start\"],ent[\"end\"],ent[\"label\"]\n",
    "        span = (start,end)\n",
    "        if span in start_end_set:\n",
    "            continue\n",
    "        else:\n",
    "            start_end_set.add(span)\n",
    "            filtered_ents.append(ent)\n",
    "    \n",
    "    filtered_dict[\"ents\"] = filtered_ents\n",
    "    filtered_output.append(filtered_dict)\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "841baa2f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'title': 'NLM_34060233',\n",
       "  'text': \"The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.INTRODUCTION: The BIN1 rs744373 single nucleotide polymorphism (SNP) is a key genetic risk locus for Alzheimer's disease (AD) associated with tau pathology. Because tau typically accumulates in response to amyloid beta (Aβ), we tested whether BIN1 rs744373 accelerates Aβ-related tau accumulation. METHODS: We included two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI], n\\xa0=\\xa0153; Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER], n\\xa0=\\xa063) with longitudinal (18) F-Flortaucipir positron emission tomography (PET), Aβ biomarkers, and longitudinal cognitive assessments. We assessed whether BIN1 rs744373 was associated with faster tau-PET accumulation at a given level of Aβ and whether faster BIN1 rs744373-associated tau-PET accumulation mediated cognitive decline. RESULTS: BIN1 rs744373 risk-allele carriers showed faster global tau-PET accumulation (ADNI/BioFINDER, P\\xa0<\\xa0.001/P\\xa0<\\xa0.001). We found significant Aβ by rs744373 interactions on global tau-PET change (ADNI: β/standard error [SE]\\xa0=\\xa00.42/0.14, P\\xa0=\\xa00.002; BioFINDER: β/SE\\xa0=\\xa0-0.35/0.15, P\\xa0=\\xa0.021), BIN1 risk-allele carriers showed accelerated tau-PET accumulation at higher Aβ levels. In ADNI, rs744373 effects on cognitive decline were mediated by faster global tau-PET accumulation (β/SE\\xa0=\\xa00.20/0.07, P\\xa0=\\xa0.005). DISCUSSION: BIN1-associated AD risk is potentially driven by accelerated tau accumulation in the face of Aβ.\",\n",
       "  'ents': [{'start': 4, 'end': 8, 'label': 'Gene'},\n",
       "   {'start': 9, 'end': 17, 'label': 'SNP'},\n",
       "   {'start': 18, 'end': 37, 'label': 'Disease'},\n",
       "   {'start': 38, 'end': 42, 'label': ''},\n",
       "   {'start': 43, 'end': 46, 'label': 'Disease'},\n",
       "   {'start': 87, 'end': 90, 'label': ''},\n",
       "   {'start': 108, 'end': 125, 'label': ''},\n",
       "   {'start': 144, 'end': 148, 'label': 'Gene'},\n",
       "   {'start': 149, 'end': 157, 'label': 'SNP'},\n",
       "   {'start': 190, 'end': 193, 'label': 'Disease'},\n",
       "   {'start': 212, 'end': 216, 'label': ''},\n",
       "   {'start': 227, 'end': 246, 'label': 'Disease'},\n",
       "   {'start': 248, 'end': 250, 'label': 'Disease'},\n",
       "   {'start': 268, 'end': 281, 'label': ''},\n",
       "   {'start': 291, 'end': 294, 'label': ''},\n",
       "   {'start': 332, 'end': 339, 'label': 'Chemical'},\n",
       "   {'start': 332, 'end': 344, 'label': ''},\n",
       "   {'start': 369, 'end': 373, 'label': 'Gene'},\n",
       "   {'start': 374, 'end': 382, 'label': 'SNP'},\n",
       "   {'start': 406, 'end': 409, 'label': ''},\n",
       "   {'start': 449, 'end': 456, 'label': ''},\n",
       "   {'start': 458, 'end': 501, 'label': ''},\n",
       "   {'start': 503, 'end': 507, 'label': ''},\n",
       "   {'start': 519, 'end': 529, 'label': ''},\n",
       "   {'start': 546, 'end': 573, 'label': 'Disease'},\n",
       "   {'start': 619, 'end': 631, 'label': 'Disease'},\n",
       "   {'start': 637, 'end': 660, 'label': 'Chemical'},\n",
       "   {'start': 652, 'end': 680, 'label': ''},\n",
       "   {'start': 682, 'end': 685, 'label': ''},\n",
       "   {'start': 691, 'end': 701, 'label': ''},\n",
       "   {'start': 707, 'end': 729, 'label': 'Disease'},\n",
       "   {'start': 720, 'end': 729, 'label': ''},\n",
       "   {'start': 763, 'end': 767, 'label': 'Gene'},\n",
       "   {'start': 768, 'end': 776, 'label': 'SNP'},\n",
       "   {'start': 804, 'end': 807, 'label': ''},\n",
       "   {'start': 808, 'end': 811, 'label': ''},\n",
       "   {'start': 867, 'end': 871, 'label': 'Gene'},\n",
       "   {'start': 872, 'end': 880, 'label': 'SNP'},\n",
       "   {'start': 892, 'end': 895, 'label': ''},\n",
       "   {'start': 896, 'end': 899, 'label': ''},\n",
       "   {'start': 922, 'end': 939, 'label': ''},\n",
       "   {'start': 950, 'end': 954, 'label': 'Gene'},\n",
       "   {'start': 955, 'end': 963, 'label': 'SNP'},\n",
       "   {'start': 964, 'end': 968, 'label': ''},\n",
       "   {'start': 1006, 'end': 1009, 'label': ''},\n",
       "   {'start': 1010, 'end': 1013, 'label': ''},\n",
       "   {'start': 1028, 'end': 1032, 'label': ''},\n",
       "   {'start': 1091, 'end': 1099, 'label': 'SNP'},\n",
       "   {'start': 1123, 'end': 1126, 'label': ''},\n",
       "   {'start': 1127, 'end': 1130, 'label': ''},\n",
       "   {'start': 1139, 'end': 1143, 'label': ''},\n",
       "   {'start': 1232, 'end': 1236, 'label': 'Gene'},\n",
       "   {'start': 1237, 'end': 1241, 'label': ''},\n",
       "   {'start': 1277, 'end': 1280, 'label': ''},\n",
       "   {'start': 1281, 'end': 1284, 'label': ''},\n",
       "   {'start': 1322, 'end': 1326, 'label': ''},\n",
       "   {'start': 1328, 'end': 1336, 'label': 'SNP'},\n",
       "   {'start': 1348, 'end': 1365, 'label': ''},\n",
       "   {'start': 1397, 'end': 1400, 'label': ''},\n",
       "   {'start': 1401, 'end': 1404, 'label': ''},\n",
       "   {'start': 1460, 'end': 1464, 'label': 'Gene'},\n",
       "   {'start': 1476, 'end': 1478, 'label': 'Disease'},\n",
       "   {'start': 1479, 'end': 1483, 'label': ''},\n",
       "   {'start': 1521, 'end': 1524, 'label': ''}]},\n",
       " {'title': 'NLM_34095440',\n",
       "  'text': \"Alzheimer's disease drug development pipeline: 2021.INTRODUCTION: The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. METHODS: We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. DISCUSSION: This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.\",\n",
       "  'ents': [{'start': 0, 'end': 19, 'label': 'Disease'},\n",
       "   {'start': 20, 'end': 24, 'label': ''},\n",
       "   {'start': 107, 'end': 126, 'label': 'Disease'},\n",
       "   {'start': 128, 'end': 130, 'label': 'Disease'},\n",
       "   {'start': 154, 'end': 158, 'label': ''},\n",
       "   {'start': 164, 'end': 174, 'label': ''},\n",
       "   {'start': 230, 'end': 235, 'label': ''},\n",
       "   {'start': 239, 'end': 254, 'label': ''},\n",
       "   {'start': 263, 'end': 272, 'label': ''},\n",
       "   {'start': 276, 'end': 278, 'label': 'Disease'},\n",
       "   {'start': 349, 'end': 364, 'label': ''},\n",
       "   {'start': 377, 'end': 382, 'label': ''},\n",
       "   {'start': 466, 'end': 468, 'label': 'Disease'},\n",
       "   {'start': 473, 'end': 483, 'label': ''},\n",
       "   {'start': 487, 'end': 494, 'label': ''},\n",
       "   {'start': 509, 'end': 516, 'label': ''},\n",
       "   {'start': 528, 'end': 535, 'label': ''},\n",
       "   {'start': 553, 'end': 558, 'label': ''},\n",
       "   {'start': 610, 'end': 612, 'label': 'Disease'},\n",
       "   {'start': 632, 'end': 639, 'label': ''},\n",
       "   {'start': 673, 'end': 682, 'label': ''},\n",
       "   {'start': 714, 'end': 719, 'label': ''},\n",
       "   {'start': 746, 'end': 771, 'label': ''},\n",
       "   {'start': 837, 'end': 846, 'label': ''},\n",
       "   {'start': 851, 'end': 855, 'label': ''},\n",
       "   {'start': 869, 'end': 879, 'label': ''},\n",
       "   {'start': 884, 'end': 888, 'label': ''},\n",
       "   {'start': 981, 'end': 990, 'label': ''},\n",
       "   {'start': 994, 'end': 996, 'label': 'Disease'}]},\n",
       " {'title': 'NLM_34101788',\n",
       "  'text': \"Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for Alzheimer's disease (AD). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or participant groups; use uniform protocols and outcome measures; and may allow treatment arms to be added or dropped based on interim analyses of outcomes. The EU/US CTAD Task Force discussed the lessons learned from the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) platform trial and the challenges addressed by other platform trials that have launched or are in the planning stages. The landscape of clinical trial platforms in the AD space includes those testing experimental therapies such as DIAN-TU, platforms designed to test multidomain interventions, and those designed to streamline trial recruitment by building trial-ready cohorts. The heterogeneity of the AD patient population, AD drugs, treatment regimens, and analytical methods complicates the design and execution of platform trials, yet Task Force members concluded that platform trials are essential to advance the search for effective AD treatments, including combination therapies.\",\n",
       "  'ents': [{'start': 28, 'end': 32, 'label': ''},\n",
       "   {'start': 48, 'end': 67, 'label': ''},\n",
       "   {'start': 199, 'end': 214, 'label': ''},\n",
       "   {'start': 219, 'end': 238, 'label': 'Disease'},\n",
       "   {'start': 240, 'end': 242, 'label': 'Disease'},\n",
       "   {'start': 314, 'end': 323, 'label': ''},\n",
       "   {'start': 337, 'end': 348, 'label': 'Species'},\n",
       "   {'start': 349, 'end': 355, 'label': ''},\n",
       "   {'start': 369, 'end': 378, 'label': ''},\n",
       "   {'start': 383, 'end': 399, 'label': ''},\n",
       "   {'start': 415, 'end': 424, 'label': ''},\n",
       "   {'start': 482, 'end': 490, 'label': ''},\n",
       "   {'start': 540, 'end': 547, 'label': ''},\n",
       "   {'start': 578, 'end': 587, 'label': 'Disease'},\n",
       "   {'start': 578, 'end': 589, 'label': ''},\n",
       "   {'start': 611, 'end': 618, 'label': 'Chemical'},\n",
       "   {'start': 667, 'end': 672, 'label': ''},\n",
       "   {'start': 722, 'end': 730, 'label': ''},\n",
       "   {'start': 731, 'end': 737, 'label': ''},\n",
       "   {'start': 756, 'end': 770, 'label': ''},\n",
       "   {'start': 788, 'end': 790, 'label': 'Disease'},\n",
       "   {'start': 851, 'end': 858, 'label': 'Chemical'},\n",
       "   {'start': 899, 'end': 912, 'label': ''},\n",
       "   {'start': 989, 'end': 996, 'label': ''},\n",
       "   {'start': 1023, 'end': 1025, 'label': 'Disease'},\n",
       "   {'start': 1026, 'end': 1033, 'label': 'Species'},\n",
       "   {'start': 1034, 'end': 1044, 'label': ''},\n",
       "   {'start': 1046, 'end': 1048, 'label': 'Disease'},\n",
       "   {'start': 1049, 'end': 1054, 'label': ''},\n",
       "   {'start': 1056, 'end': 1065, 'label': ''},\n",
       "   {'start': 1260, 'end': 1262, 'label': 'Disease'},\n",
       "   {'start': 1263, 'end': 1273, 'label': ''}]},\n",
       " {'title': 'NLM_33730588',\n",
       "  'text': \"The AD tau core spontaneously self-assembles and recruits full-length tau to filaments.Tau accumulation is a major pathological hallmark of Alzheimer's disease (AD) and other tauopathies, but the mechanism(s) of tau aggregation remains unclear. Taking advantage of the identification of tau filament cores by cryoelectron microscopy, we demonstrate that the AD tau core possesses the intrinsic ability to spontaneously aggregate in the absence of an inducer, with antibodies generated against AD tau core filaments detecting AD tau pathology. The AD tau core also drives aggregation of full-length wild-type tau, increases seeding potential, and templates abnormal forms of tau present in brain homogenates and antemortem cerebrospinal fluid (CSF) from patients with AD in an ultrasensitive real-time quaking-induced conversion (QuIC) assay. Finally, we show that the filament cores in corticobasal degeneration (CBD) and Pick's disease (PiD) similarly assemble into filaments under physiological conditions. These results document an approach to modeling tau aggregation and have significant implications for in\\xa0vivo investigation of tau transmission and biomarker development.\",\n",
       "  'ents': [{'start': 4, 'end': 6, 'label': ''},\n",
       "   {'start': 7, 'end': 10, 'label': ''},\n",
       "   {'start': 11, 'end': 15, 'label': ''},\n",
       "   {'start': 70, 'end': 73, 'label': ''},\n",
       "   {'start': 77, 'end': 86, 'label': ''},\n",
       "   {'start': 87, 'end': 90, 'label': ''},\n",
       "   {'start': 128, 'end': 159, 'label': 'Disease'},\n",
       "   {'start': 140, 'end': 159, 'label': ''},\n",
       "   {'start': 161, 'end': 163, 'label': ''},\n",
       "   {'start': 169, 'end': 174, 'label': ''},\n",
       "   {'start': 175, 'end': 186, 'label': 'Disease'},\n",
       "   {'start': 212, 'end': 227, 'label': 'Disease'},\n",
       "   {'start': 212, 'end': 215, 'label': ''},\n",
       "   {'start': 216, 'end': 227, 'label': ''},\n",
       "   {'start': 287, 'end': 290, 'label': ''},\n",
       "   {'start': 291, 'end': 299, 'label': ''},\n",
       "   {'start': 300, 'end': 305, 'label': ''},\n",
       "   {'start': 358, 'end': 360, 'label': ''},\n",
       "   {'start': 361, 'end': 364, 'label': ''},\n",
       "   {'start': 365, 'end': 369, 'label': ''},\n",
       "   {'start': 464, 'end': 474, 'label': ''},\n",
       "   {'start': 493, 'end': 495, 'label': ''},\n",
       "   {'start': 496, 'end': 499, 'label': ''},\n",
       "   {'start': 500, 'end': 504, 'label': ''},\n",
       "   {'start': 505, 'end': 514, 'label': ''},\n",
       "   {'start': 525, 'end': 527, 'label': ''},\n",
       "   {'start': 528, 'end': 541, 'label': ''},\n",
       "   {'start': 547, 'end': 549, 'label': ''},\n",
       "   {'start': 550, 'end': 553, 'label': ''},\n",
       "   {'start': 554, 'end': 558, 'label': ''},\n",
       "   {'start': 571, 'end': 582, 'label': ''},\n",
       "   {'start': 608, 'end': 611, 'label': ''},\n",
       "   {'start': 674, 'end': 677, 'label': ''},\n",
       "   {'start': 689, 'end': 694, 'label': ''},\n",
       "   {'start': 722, 'end': 741, 'label': ''},\n",
       "   {'start': 743, 'end': 746, 'label': ''},\n",
       "   {'start': 753, 'end': 761, 'label': 'Species'},\n",
       "   {'start': 767, 'end': 769, 'label': ''},\n",
       "   {'start': 835, 'end': 840, 'label': ''},\n",
       "   {'start': 868, 'end': 876, 'label': ''},\n",
       "   {'start': 877, 'end': 882, 'label': ''},\n",
       "   {'start': 886, 'end': 911, 'label': ''},\n",
       "   {'start': 922, 'end': 936, 'label': 'Disease'},\n",
       "   {'start': 929, 'end': 936, 'label': ''},\n",
       "   {'start': 967, 'end': 976, 'label': ''},\n",
       "   {'start': 1023, 'end': 1031, 'label': ''},\n",
       "   {'start': 1047, 'end': 1055, 'label': ''},\n",
       "   {'start': 1056, 'end': 1071, 'label': 'Disease'},\n",
       "   {'start': 1056, 'end': 1059, 'label': ''},\n",
       "   {'start': 1060, 'end': 1071, 'label': ''},\n",
       "   {'start': 1135, 'end': 1138, 'label': ''},\n",
       "   {'start': 1156, 'end': 1165, 'label': ''}]},\n",
       " {'title': 'NLM_33988687',\n",
       "  'text': \"Alzheimer mutant speeds APP transport.APPS198P segregates with rare familial forms of Alzheimer's disease and resides within exon 5, unlike 27 other mutations that reside in exons 16 or 17. In this issue, Zhang et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210313) show that the brains of APPS198P transgenic mice accumulate excess levels of Aβ. In cultured cells, APPS198P undergoes accelerated ER folding, leading to early arrival in late vesicular compartments, thereby enhancing generation of Aβ.\",\n",
       "  'ents': [{'start': 0, 'end': 9, 'label': 'Disease'},\n",
       "   {'start': 24, 'end': 27, 'label': ''},\n",
       "   {'start': 86, 'end': 105, 'label': 'Disease'},\n",
       "   {'start': 143, 'end': 148, 'label': ''},\n",
       "   {'start': 149, 'end': 158, 'label': ''},\n",
       "   {'start': 289, 'end': 295, 'label': ''},\n",
       "   {'start': 308, 'end': 323, 'label': 'Species'},\n",
       "   {'start': 319, 'end': 323, 'label': ''},\n",
       "   {'start': 359, 'end': 373, 'label': ''}]},\n",
       " {'title': 'NLM_33958804',\n",
       "  'text': \"Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease.Selective neurodegeneration is a critical causal factor in Alzheimer's disease (AD); however, the mechanisms that lead some neurons to perish, whereas others remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-nucleus RNA sequencing and discovered that ApoE expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of ApoE-which has a robust genetic linkage to AD-correlated strongly, on a cell-by-cell basis, with immune response pathways in neurons in the brains of wild-type mice, human ApoE knock-in mice and humans with or without AD. Elimination or over-expression of neuronal ApoE revealed a causal relationship among ApoE expression, neuronal MHC-I expression, tau pathology and neurodegeneration. Functional reduction of MHC-I ameliorated tau pathology in ApoE4-expressing primary neurons and in mouse hippocampi expressing pathological tau. These findings suggest a mechanism linking neuronal ApoE expression to MHC-I expression and, subsequently, to tau pathology and selective neurodegeneration.\",\n",
       "  'ents': [{'start': 9, 'end': 13, 'label': 'Gene'},\n",
       "   {'start': 62, 'end': 79, 'label': 'Disease'},\n",
       "   {'start': 83, 'end': 102, 'label': 'Disease'},\n",
       "   {'start': 113, 'end': 130, 'label': 'Disease'},\n",
       "   {'start': 162, 'end': 181, 'label': 'Disease'},\n",
       "   {'start': 183, 'end': 185, 'label': 'Disease'},\n",
       "   {'start': 227, 'end': 234, 'label': ''},\n",
       "   {'start': 254, 'end': 260, 'label': ''},\n",
       "   {'start': 365, 'end': 372, 'label': ''},\n",
       "   {'start': 373, 'end': 376, 'label': ''},\n",
       "   {'start': 408, 'end': 412, 'label': 'Gene'},\n",
       "   {'start': 514, 'end': 518, 'label': 'Gene'},\n",
       "   {'start': 557, 'end': 559, 'label': 'Disease'},\n",
       "   {'start': 639, 'end': 646, 'label': ''},\n",
       "   {'start': 654, 'end': 660, 'label': ''},\n",
       "   {'start': 674, 'end': 678, 'label': 'Species'},\n",
       "   {'start': 680, 'end': 685, 'label': 'Species'},\n",
       "   {'start': 686, 'end': 690, 'label': 'Gene'},\n",
       "   {'start': 700, 'end': 704, 'label': 'Species'},\n",
       "   {'start': 709, 'end': 715, 'label': 'Species'},\n",
       "   {'start': 732, 'end': 734, 'label': 'Disease'},\n",
       "   {'start': 779, 'end': 783, 'label': 'Gene'},\n",
       "   {'start': 821, 'end': 825, 'label': 'Gene'},\n",
       "   {'start': 865, 'end': 878, 'label': ''},\n",
       "   {'start': 883, 'end': 900, 'label': 'Disease'},\n",
       "   {'start': 944, 'end': 957, 'label': ''},\n",
       "   {'start': 961, 'end': 966, 'label': ''},\n",
       "   {'start': 986, 'end': 993, 'label': ''},\n",
       "   {'start': 1001, 'end': 1006, 'label': 'Species'},\n",
       "   {'start': 1007, 'end': 1017, 'label': ''},\n",
       "   {'start': 1042, 'end': 1045, 'label': ''},\n",
       "   {'start': 1099, 'end': 1103, 'label': 'Gene'},\n",
       "   {'start': 1157, 'end': 1170, 'label': ''},\n",
       "   {'start': 1185, 'end': 1202, 'label': 'Disease'}]},\n",
       " {'title': 'NLM_31721178',\n",
       "  'text': \"Tau (297-391) forms filaments that structurally mimic the core of paired helical filaments in Alzheimer's disease brain.The constituent paired helical filaments (PHFs) in neurofibrillary tangles are insoluble intracellular deposits central to the development of Alzheimer's disease (AD) and other tauopathies. Full-length tau requires the addition of anionic cofactors such as heparin to enhance assembly. We have shown that a fragment from the proteolytically stable core of the PHF, tau 297-391 known as 'dGAE', spontaneously forms cross-β-containing PHFs and straight filaments under physiological conditions. Here, we have analysed and compared the structures of the filaments formed by dGAE in\\xa0vitro with those deposited in the brains of individuals diagnosed with AD. We show that dGAE forms PHFs that share a macromolecular structure similar to those found in brain tissue. Thus, dGAEs may serve as a model system for studying core domain assembly and for screening for inhibitors of tau aggregation.\",\n",
       "  'ents': [{'start': 0, 'end': 3, 'label': ''},\n",
       "   {'start': 20, 'end': 29, 'label': ''},\n",
       "   {'start': 58, 'end': 62, 'label': ''},\n",
       "   {'start': 81, 'end': 90, 'label': ''},\n",
       "   {'start': 94, 'end': 113, 'label': 'Disease'},\n",
       "   {'start': 114, 'end': 119, 'label': ''},\n",
       "   {'start': 151, 'end': 160, 'label': ''},\n",
       "   {'start': 171, 'end': 194, 'label': ''},\n",
       "   {'start': 262, 'end': 281, 'label': 'Disease'},\n",
       "   {'start': 283, 'end': 285, 'label': 'Disease'},\n",
       "   {'start': 291, 'end': 296, 'label': ''},\n",
       "   {'start': 297, 'end': 308, 'label': 'Disease'},\n",
       "   {'start': 322, 'end': 325, 'label': ''},\n",
       "   {'start': 377, 'end': 384, 'label': 'Chemical'},\n",
       "   {'start': 468, 'end': 472, 'label': ''},\n",
       "   {'start': 485, 'end': 488, 'label': ''},\n",
       "   {'start': 571, 'end': 580, 'label': ''},\n",
       "   {'start': 671, 'end': 680, 'label': ''},\n",
       "   {'start': 733, 'end': 739, 'label': ''},\n",
       "   {'start': 770, 'end': 772, 'label': 'Disease'},\n",
       "   {'start': 867, 'end': 879, 'label': ''},\n",
       "   {'start': 908, 'end': 913, 'label': ''},\n",
       "   {'start': 925, 'end': 933, 'label': ''},\n",
       "   {'start': 934, 'end': 938, 'label': ''},\n",
       "   {'start': 963, 'end': 972, 'label': ''},\n",
       "   {'start': 977, 'end': 987, 'label': ''},\n",
       "   {'start': 991, 'end': 1006, 'label': 'Disease'},\n",
       "   {'start': 991, 'end': 994, 'label': ''},\n",
       "   {'start': 995, 'end': 1006, 'label': ''}]},\n",
       " {'title': 'CCC_000637925000033',\n",
       "  'text': 'Glycoengineering artificial receptors for microglia to phagocytose A beta aggregates.Oligomeric and fibrillar amyloid-beta (A beta) are principally internalized via receptor-mediated endocytosis (RME) by microglia, the main scavenger of A beta in the brain. Nevertheless, the inflammatory cascade will be evoked after vast A beta aggregate binding to pattern recognition receptors on the cell membrane, which then significantly decreases the expression of these receptors and further deteriorate A beta deposition. This vicious circle will weaken the ability of microglia for A beta elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial membranes with ThS as artificial A beta receptors to promote microglia to phagocytose A beta aggregates. Additionally, to circumvent the undesirable immune response during the process of the bioorthogonal chemistry reaction and A beta-microglial interaction, Mn-porphyrin metal-organic frameworks (Mn-MOFs) with superoxide dismutase (SOD) and catalase (CAT) mimic activity are employed to carry N-azidoacetylmannosamine (AcManNAz) and eradicate over-expressed reactive oxygen species (ROSs). The artificial A beta receptors independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with antioxidant properties can synergistically promote the phagocytosis and clearance of A beta with significantly enhanced activity and negligible adverse effects. The present study will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for other disease intervention associated with receptor starvation.',\n",
       "  'ents': [{'start': 28, 'end': 37, 'label': ''},\n",
       "   {'start': 42, 'end': 51, 'label': ''},\n",
       "   {'start': 67, 'end': 73, 'label': 'Gene'},\n",
       "   {'start': 110, 'end': 122, 'label': 'Chemical'},\n",
       "   {'start': 124, 'end': 130, 'label': 'Gene'},\n",
       "   {'start': 165, 'end': 173, 'label': ''},\n",
       "   {'start': 183, 'end': 194, 'label': ''},\n",
       "   {'start': 196, 'end': 199, 'label': 'Chemical'},\n",
       "   {'start': 204, 'end': 213, 'label': ''},\n",
       "   {'start': 237, 'end': 243, 'label': 'Gene'},\n",
       "   {'start': 251, 'end': 256, 'label': ''},\n",
       "   {'start': 276, 'end': 296, 'label': ''},\n",
       "   {'start': 323, 'end': 329, 'label': 'Gene'},\n",
       "   {'start': 371, 'end': 380, 'label': ''},\n",
       "   {'start': 393, 'end': 401, 'label': ''},\n",
       "   {'start': 462, 'end': 471, 'label': ''},\n",
       "   {'start': 496, 'end': 502, 'label': 'Gene'},\n",
       "   {'start': 562, 'end': 571, 'label': ''},\n",
       "   {'start': 576, 'end': 582, 'label': 'Gene'},\n",
       "   {'start': 718, 'end': 727, 'label': ''},\n",
       "   {'start': 751, 'end': 757, 'label': 'Gene'},\n",
       "   {'start': 758, 'end': 767, 'label': ''},\n",
       "   {'start': 779, 'end': 788, 'label': ''},\n",
       "   {'start': 804, 'end': 810, 'label': 'Gene'},\n",
       "   {'start': 894, 'end': 901, 'label': ''},\n",
       "   {'start': 946, 'end': 952, 'label': 'Gene'},\n",
       "   {'start': 977, 'end': 989, 'label': 'Chemical'},\n",
       "   {'start': 1016, 'end': 1023, 'label': 'Chemical'},\n",
       "   {'start': 1030, 'end': 1050, 'label': 'Gene'},\n",
       "   {'start': 1052, 'end': 1055, 'label': 'Gene'},\n",
       "   {'start': 1061, 'end': 1069, 'label': 'Gene'},\n",
       "   {'start': 1071, 'end': 1074, 'label': 'Gene'},\n",
       "   {'start': 1113, 'end': 1137, 'label': 'Chemical'},\n",
       "   {'start': 1187, 'end': 1193, 'label': 'Chemical'},\n",
       "   {'start': 1225, 'end': 1231, 'label': 'Gene'},\n",
       "   {'start': 1232, 'end': 1241, 'label': ''},\n",
       "   {'start': 1327, 'end': 1338, 'label': ''},\n",
       "   {'start': 1382, 'end': 1394, 'label': ''},\n",
       "   {'start': 1412, 'end': 1418, 'label': 'Gene'},\n",
       "   {'start': 1500, 'end': 1505, 'label': ''},\n",
       "   {'start': 1680, 'end': 1685, 'label': ''},\n",
       "   {'start': 1686, 'end': 1693, 'label': ''},\n",
       "   {'start': 1694, 'end': 1706, 'label': ''},\n",
       "   {'start': 1723, 'end': 1731, 'label': ''}]},\n",
       " {'title': 'CCC_000647663200001',\n",
       "  'text': 'Impairment of visual cortical plasticity by amyloid-beta species.Introduction: A variety of transgenic and knock-in mice that express mutant alleles of Amyloid precursor protein (APP) have been used to model the effects of amyloid-beta (A?) on circuit function in Alzheimer?s disease (AD); however phenotypes described in these mice may be affected by expression of mutant APP or proteolytic cleavage products independent of A?. In addition, the effects of mutant APP expression are attributed to elevated expression of the amyloidogenic, 42-amino acid-long species of A? (A?42) associated with amyloid plaque accumulation in AD, though elevated concentrations of A?40, an A? species produced with normal synaptic activity, may also affect neural function. Methods: To explore the effects of elevated expression of A? on synaptic function in vivo, we assessed visual system plasticity in transgenic mice that express and secrete A? throughout the brain in the absence of APP overexpression. Transgenic mice that express either A?40 or A?42 were assayed for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation. Results: Using two complementary approaches to measure the plastic response to monocular deprivation, we find that male and female mice that express either 40- or 42-amino acid?long A? species demonstrate a plasticity defect comparable to that elicited in transgenic mice that express mutant alleles of APP and Presenilin 1 (APP/PS1 mice). Conclusions: These data support the hypothesis that mutant APP-driven plasticity impairment in mouse models of AD is mediated by production and accumulation of A?. Moreover, these findings suggest that soluble species of A? are capable of modulating synaptic plasticity, likely independent of any aggregation. These findings may have implications for the role of soluble species of A? in both development and disease settings.',\n",
       "  'ents': [{'start': 0, 'end': 40, 'label': 'Disease'},\n",
       "   {'start': 44, 'end': 51, 'label': 'Chemical'},\n",
       "   {'start': 44, 'end': 56, 'label': ''},\n",
       "   {'start': 116, 'end': 120, 'label': 'Species'},\n",
       "   {'start': 152, 'end': 177, 'label': 'Gene'},\n",
       "   {'start': 179, 'end': 182, 'label': ''},\n",
       "   {'start': 202, 'end': 207, 'label': ''},\n",
       "   {'start': 223, 'end': 235, 'label': 'Chemical'},\n",
       "   {'start': 252, 'end': 260, 'label': ''},\n",
       "   {'start': 264, 'end': 273, 'label': 'Disease'},\n",
       "   {'start': 264, 'end': 283, 'label': ''},\n",
       "   {'start': 274, 'end': 283, 'label': 'Disease'},\n",
       "   {'start': 285, 'end': 287, 'label': 'Disease'},\n",
       "   {'start': 298, 'end': 308, 'label': ''},\n",
       "   {'start': 328, 'end': 332, 'label': 'Species'},\n",
       "   {'start': 373, 'end': 376, 'label': ''},\n",
       "   {'start': 464, 'end': 467, 'label': ''},\n",
       "   {'start': 524, 'end': 537, 'label': 'Chemical'},\n",
       "   {'start': 539, 'end': 552, 'label': 'Chemical'},\n",
       "   {'start': 595, 'end': 602, 'label': 'Chemical'},\n",
       "   {'start': 595, 'end': 609, 'label': ''},\n",
       "   {'start': 626, 'end': 628, 'label': 'Disease'},\n",
       "   {'start': 747, 'end': 755, 'label': ''},\n",
       "   {'start': 830, 'end': 838, 'label': ''},\n",
       "   {'start': 842, 'end': 846, 'label': ''},\n",
       "   {'start': 888, 'end': 903, 'label': 'Species'},\n",
       "   {'start': 899, 'end': 903, 'label': ''},\n",
       "   {'start': 947, 'end': 952, 'label': ''},\n",
       "   {'start': 971, 'end': 974, 'label': ''},\n",
       "   {'start': 991, 'end': 1006, 'label': 'Species'},\n",
       "   {'start': 1002, 'end': 1006, 'label': ''},\n",
       "   {'start': 1045, 'end': 1052, 'label': ''},\n",
       "   {'start': 1276, 'end': 1280, 'label': ''},\n",
       "   {'start': 1285, 'end': 1291, 'label': ''},\n",
       "   {'start': 1292, 'end': 1296, 'label': 'Species'},\n",
       "   {'start': 1324, 'end': 1337, 'label': 'Chemical'},\n",
       "   {'start': 1417, 'end': 1432, 'label': 'Species'},\n",
       "   {'start': 1428, 'end': 1432, 'label': ''},\n",
       "   {'start': 1464, 'end': 1467, 'label': ''},\n",
       "   {'start': 1472, 'end': 1484, 'label': 'Gene'},\n",
       "   {'start': 1486, 'end': 1489, 'label': ''},\n",
       "   {'start': 1490, 'end': 1493, 'label': 'Gene'},\n",
       "   {'start': 1494, 'end': 1498, 'label': 'Species'},\n",
       "   {'start': 1560, 'end': 1563, 'label': ''},\n",
       "   {'start': 1596, 'end': 1601, 'label': 'Species'},\n",
       "   {'start': 1596, 'end': 1608, 'label': ''},\n",
       "   {'start': 1612, 'end': 1614, 'label': 'Disease'},\n",
       "   {'start': 1798, 'end': 1809, 'label': ''},\n",
       "   {'start': 1856, 'end': 1863, 'label': ''},\n",
       "   {'start': 1910, 'end': 1917, 'label': ''}]},\n",
       " {'title': 'CCC_000653155500009',\n",
       "  'text': \"An excellent electrochemical aptasensor for amyloid-beta oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events.An excellent aptasensor for electrochemical detection of amyloid-beta oligomers (A beta Os) at trace levels was fabricated based on a triple-helix aptamer switch (THAS) via target-triggered signal transduction DNA displacement events. Specifically, a single-stranded anti-A beta O aptamer (Apt) carrying two symmetrical arm segments was first attached via Au-S binding to an Au electrode. Gold nanoparticle (GNP)-tagged signal transduction probes (GNP-STPs) were simultaneously hybridized with the two arm segments of the Apt, and a rigid THAS was formed on the Au electrode. Compared to the conventional hybrid, the number of GNPs on the Au electrode increased significantly with the THAS, effectively improving the stability of the Apt to avoid lodging. Trithiocyanuric acid (TA) was utilized to further gather the GNPs and form network-like TA/GNPs. As a result, the differential pulse voltammetry (DPV) response of GNPs was clearly enhanced. When A beta Os were present, target-triggered signal transduction DNA displacement events were carried out from THAS via the reaction of the Apt with the A beta Os, which caused the GNP-STP to dissociate from the Au electrode, and thus a significant reduction in the DPV response was observed. The assay was able to sensitively detect trace A beta Os by monitoring the A beta O-controlled DPV response change. It exhibited a wide linear range from 1 fM to 10 pM with a low detection limit of 0.5 fM, and was successfully employed for the determination of A beta Os in 20 serum samples, with good recovery. Moreover, the developed assay can provide a sensitive and selective platform for many studies or investigations related to Alzheimer's disease (AD) monitoring and treatment.\",\n",
       "  'ents': [{'start': 44, 'end': 51, 'label': 'Chemical'},\n",
       "   {'start': 44, 'end': 56, 'label': ''},\n",
       "   {'start': 228, 'end': 235, 'label': 'Chemical'},\n",
       "   {'start': 228, 'end': 240, 'label': ''},\n",
       "   {'start': 927, 'end': 947, 'label': 'Chemical'},\n",
       "   {'start': 949, 'end': 951, 'label': 'Chemical'},\n",
       "   {'start': 1010, 'end': 1014, 'label': ''},\n",
       "   {'start': 1015, 'end': 1017, 'label': 'Chemical'},\n",
       "   {'start': 1122, 'end': 1128, 'label': 'Gene'},\n",
       "   {'start': 1271, 'end': 1277, 'label': 'Gene'},\n",
       "   {'start': 1415, 'end': 1420, 'label': ''},\n",
       "   {'start': 1458, 'end': 1464, 'label': 'Gene'},\n",
       "   {'start': 1486, 'end': 1492, 'label': 'Gene'},\n",
       "   {'start': 1672, 'end': 1678, 'label': 'Gene'},\n",
       "   {'start': 1694, 'end': 1701, 'label': ''},\n",
       "   {'start': 1747, 'end': 1752, 'label': ''},\n",
       "   {'start': 1804, 'end': 1808, 'label': ''},\n",
       "   {'start': 1809, 'end': 1816, 'label': ''},\n",
       "   {'start': 1846, 'end': 1865, 'label': 'Disease'},\n",
       "   {'start': 1867, 'end': 1869, 'label': 'Disease'},\n",
       "   {'start': 1886, 'end': 1895, 'label': ''}]}]"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "af4b5065",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><h2 style=\"margin: 0\">NLM_34060233</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SNP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " is associated with faster Aβ-associated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive decline\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".INTRODUCTION: The \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " single nucleotide polymorphism (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SNP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") is a key genetic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " locus for \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") associated with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Because \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " typically accumulates in response to \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (Aβ), we tested whether \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " accelerates Aβ-related \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation. METHODS: We included two \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    samples\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's Disease Neuroimaging Initiative\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " [\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "], n = 153; \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Biomarkers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for Identifying \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Neurodegenerative Disorders\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " Early and Reliably [BioFINDER], n = 63) with \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    longitudinal\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (18) \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    F-Flortaucipir positron\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    positron emission tomography\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "), Aβ \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    biomarkers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    longitudinal cognitive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " assessments. We assessed whether \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " was associated with faster \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation at a given level of Aβ and whether faster \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       "-associated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation mediated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive decline\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". RESULTS: \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-allele carriers showed faster global \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "/BioFINDER, P &lt; .001/P &lt; .001). We found significant Aβ by \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " interactions on global \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " change (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ": β/standard error [SE] = 0.42/0.14, P = 0.002; BioFINDER: β/SE = -0.35/0.15, P = .021), \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-allele carriers showed accelerated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation at higher Aβ levels. In \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADNI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: moccasin; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rs744373\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">SNP</span>\n",
       "</mark>\n",
       " effects on \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive decline\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " were mediated by faster global \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PET\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation (β/SE = 0.20/0.07, P = .005). DISCUSSION: \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    BIN1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       "-associated \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    risk\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " is potentially driven by accelerated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation in the face of Aβ.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34095440</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drug\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " development pipeline: 2021.INTRODUCTION: The number of individuals worldwide with \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") is growing at a rapid \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". New \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are urgently needed. We review the current pipeline of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trials\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". METHODS: We interrogated ClinicalTrials.gov, the federal registry of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trials\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to identify \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in trials. RESULTS: There are 126 agents in 152 trials assessing new therapies for \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ": 28 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phase 3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " trials, 74 in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phase 2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", and 24 in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phase 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The majority of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in trials (82.5%) target the underlying biology of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " with the intent of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " modification; 10.3% are putative \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cognitive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " enhancing agents; and 7.1% are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " being developed to reduce \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neuropsychiatric symptoms\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". DISCUSSION: This pipeline analysis shows that target biological \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    processes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    more\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " diversified, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    biomarkers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    more\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " regularly used, and repurposed agents are being explored to determine their utility for the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_34101788</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Platform Trials to Expedite \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Drug\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " Development in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's Disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ": A Report from the EU/US CTAD Task Force.A diverse range of platforms has been established to increase the efficiency and speed of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trials\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "). These platforms enable parallel assessment of multiple therapeutics, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " regimens, or \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    participant\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    groups\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "; use uniform \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    protocols\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    outcome measures\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "; and may allow \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " arms to be added or dropped based on interim analyses of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    outcomes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The EU/US CTAD Task Force discussed the lessons \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    learned\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " from the Dominantly Inherited \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " Network Trials Unit (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DIAN-TU\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") platform trial and the challenges addressed by \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " platform trials that have launched or are in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    planning\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    stages\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The landscape of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clinical trial\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " platforms in the \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " space includes those testing experimental therapies such as \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    DIAN-TU\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ", platforms designed to test multidomain \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    interventions\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", and those designed to streamline trial recruitment by building trial-ready \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cohorts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The heterogeneity of the \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    patient\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    population\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    drugs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " regimens, and analytical methods complicates the design and execution of platform trials, yet Task Force members concluded that platform trials are essential to advance the search for effective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", including combination therapies.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33730588</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " spontaneously self-assembles and recruits full-length \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation is a major pathological \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hallmark of Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tauopathies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ", but the mechanism(s) of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " remains unclear. Taking advantage of the identification of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filament\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cores\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " by cryoelectron microscopy, we demonstrate that the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " possesses the intrinsic ability to spontaneously aggregate in the absence of an inducer, with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    antibodies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " generated against \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " detecting \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " also drives \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of full-length wild-type \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", increases seeding potential, and templates abnormal forms of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " present in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " homogenates and antemortem \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cerebrospinal fluid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CSF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") from \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    patients\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in an ultrasensitive real-time quaking-induced conversion (QuIC) \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assay\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Finally, we show that the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filament\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cores\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    corticobasal degeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (CBD) and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pick's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (PiD) similarly assemble into \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " under physiological conditions. These results \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    document\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " an approach to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    modeling\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and have significant implications for in vivo investigation of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " transmission and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    biomarker\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " development.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33988687</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " mutant speeds \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " transport.APPS198P segregates with rare familial forms of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " and resides within exon 5, unlike 27 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mutations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that reside in exons 16 or 17. In this issue, Zhang et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210313) show that the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brains\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of APPS198P \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulate excess levels of Aβ. In \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cultured cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", APPS198P undergoes accelerated ER folding, leading to early arrival in late vesicular compartments, thereby enhancing generation of Aβ.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_33958804</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Neuronal \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " upregulates MHC-I expression to drive selective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".Selective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " is a critical causal factor in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "); however, the mechanisms that lead some \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurons\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to perish, whereas \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    others\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nucleus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " sequencing and discovered that \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       "-which has a robust genetic linkage to \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "-correlated strongly, on a cell-by-cell basis, with immune response pathways in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurons\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brains\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of wild-type \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    human\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " knock-in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    humans\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " with or without \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Elimination or over-expression of neuronal \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " revealed a causal relationship among \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " expression, neuronal MHC-I expression, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Functional reduction of MHC-I ameliorated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-expressing primary \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurons\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hippocampi\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expressing pathological \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". These findings suggest a mechanism linking neuronal \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ApoE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " expression to MHC-I expression and, subsequently, to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau pathology\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and selective \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurodegeneration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">NLM_31721178</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (297-391) forms \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that structurally mimic the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of paired helical \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".The constituent paired helical \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (PHFs) in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    neurofibrillary tangles\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " are insoluble intracellular deposits central to the development of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tauopathies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Full-length \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " requires the addition of anionic cofactors such as \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heparin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " to enhance assembly. We have shown that a fragment from the proteolytically stable \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of the PHF, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " 297-391 known as 'dGAE', spontaneously forms cross-β-containing PHFs and straight \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " under physiological conditions. Here, we have analysed and compared the structures of the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    filaments\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " formed by dGAE in vitro with those deposited in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brains\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of individuals diagnosed with \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". We show that dGAE forms PHFs that share a macromolecular structure similar to those found in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Thus, dGAEs may serve as a \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    model\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " system for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    studying\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    core\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " domain assembly and for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    screening\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    inhibitors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tau\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000637925000033</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Glycoengineering artificial \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to phagocytose \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " aggregates.Oligomeric and fibrillar \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       ") are principally internalized via \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-mediated \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    endocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RME\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") by \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", the main scavenger of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " in the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Nevertheless, the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    inflammatory cascade\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " will be evoked after vast \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " aggregate binding to pattern recognition \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " on the cell \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    membrane\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", which then significantly decreases the expression of these \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and further deteriorate \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " deposition. This vicious circle will weaken the ability of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " elimination. Herein, a combination of metabolic glycoengineering and self-triggered click chemistry is utilized to engineer microglial \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    membranes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " with ThS as artificial \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to promote \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    microglia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " to phagocytose \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " aggregates. Additionally, to circumvent the undesirable immune response during the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    process\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of the bioorthogonal chemistry reaction and \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       "-microglial interaction, \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mn-porphyrin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " metal-organic frameworks (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Mn-MOFs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") with \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    superoxide dismutase\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SOD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       ") and \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalase\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CAT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       ") mimic activity are employed to carry \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    N-azidoacetylmannosamine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (AcManNAz) and eradicate over-expressed reactive \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    oxygen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " species (ROSs). The artificial \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " independent of a signal pathway involved in immunomodulation as well as Mn-MOFs with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    antioxidant\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " properties can synergistically promote the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    phagocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and clearance of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " with significantly enhanced activity and negligible adverse effects. The present \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    study\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " will not only provide valuable insight into the rational design of the microglial surface engineering strategy via bioorthogonal chemistry, but also hold great potential for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    other\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    intervention\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " associated with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    receptor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " starvation.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000647663200001</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Impairment of visual cortical plasticity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " by \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " species.Introduction: A variety of transgenic and knock-in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express mutant alleles of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amyloid precursor protein\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ") have been used to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    model\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " the effects of \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (A?) on circuit \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    function\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer?s disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "); however \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    phenotypes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " described in these \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " may be affected by expression of mutant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " or proteolytic cleavage products independent of A?. In addition, the effects of mutant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " expression are attributed to elevated expression of the \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloidogenic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    42-amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "-long species of A? (A?42) associated with \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid plaque\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " accumulation in \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ", though elevated concentrations of A?40, an A? species produced with normal synaptic activity, may also affect neural \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    function\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". Methods: To explore the effects of elevated expression of A? on synaptic \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    function\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vivo\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", we assessed visual system plasticity in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express and secrete A? throughout the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    brain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " in the absence of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " overexpression. \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express either A?40 or A?42 were \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assayed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " for their ability to appropriately demonstrate ocular dominance plasticity following monocular deprivation. Results: Using two complementary approaches to measure the plastic response to monocular deprivation, we find that \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    male\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    female\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       " that express either 40- or \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    42-amino acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "?long A? species demonstrate a plasticity defect comparable to that elicited in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    transgenic mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " that express mutant alleles of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Presenilin 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PS1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mice\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "). Conclusions: These data support the hypothesis that mutant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    APP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       "-driven plasticity impairment in \n",
       "<mark class=\"entity\" style=\"background: lightgreen; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Species</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mouse models\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " is mediated by production and accumulation of A?. Moreover, these findings suggest that soluble species of A? are capable of modulating synaptic plasticity, likely independent of any \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aggregation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ". These findings may have implications for the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    role of\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " soluble species of A? in both development and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " settings.</div>\n",
       "\n",
       "<h2 style=\"margin: 0\">CCC_000653155500009</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">An excellent electrochemical aptasensor for \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events.An excellent aptasensor for electrochemical detection of \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amyloid-beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " oligomers (A beta Os) at trace levels was fabricated based on a triple-helix aptamer switch (THAS) via target-triggered signal transduction DNA displacement events. Specifically, a single-stranded anti-A beta O aptamer (Apt) carrying two symmetrical arm segments was first attached via Au-S binding to an Au electrode. Gold nanoparticle (GNP)-tagged signal transduction probes (GNP-STPs) were simultaneously hybridized with the two arm segments of the Apt, and a rigid THAS was formed on the Au electrode. Compared to the conventional hybrid, the number of GNPs on the Au electrode increased significantly with the THAS, effectively improving the stability of the Apt to avoid lodging. \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Trithiocyanuric acid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       ") was utilized to further gather the GNPs and form network-\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    like\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: violet; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Chemical</span>\n",
       "</mark>\n",
       "/GNPs. As a result, the differential pulse voltammetry (DPV) response of GNPs was clearly enhanced. When \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os were present, target-triggered signal transduction DNA displacement events were carried out from THAS via the reaction of the Apt with the \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os, which caused the GNP-STP to dissociate from the Au electrode, and thus a significant reduction in the DPV response was observed. The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assay\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " was able to sensitively detect trace \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os by monitoring the \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " O-controlled DPV response change. It exhibited a wide linear range from 1 fM to 10 pM with a low detection limit of 0.5 fM, and was successfully employed for the determination of \n",
       "<mark class=\"entity\" style=\"background: aqua; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A beta\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Gene</span>\n",
       "</mark>\n",
       " Os in 20 serum \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    samples\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ", with good recovery. Moreover, the developed \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    assay\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " can provide a sensitive and selective platform for \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    many\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    studies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       " or investigations related to \n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: pink; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ") monitoring and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    treatment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\"></span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(filtered_output, style=\"ent\", manual=True, \n",
    "                options={\"colors\":{\"GENE\":\"aqua\", \"DISEASE\":\"pink\", \"CHEMICAL\":\"violet\",\n",
    "                                   \"SNP\":\"moccasin\", \"SPECIES\":\"lightgreen\"}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "874d5fb2",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "28e17d87",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "cf73afe0",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0376c834",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "41063a7c",
   "metadata": {},
   "source": [
    "### ignore the lines below"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "a9dc92d5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# html = displacy.render(docs, style=\"ent\", manual=True, options={\"colors\":{}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "e0e89796",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # errors for the html\n",
    "# html_path = \"/Users/yidesdo21/Projects/outputs/03_annotation_with_articles/html/\"\n",
    "# with open(html_path+\"test.html\", \"w\") as f:\n",
    "#     f.write(html)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "28a1d5ea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><h2 style=\"margin: 0\">Test</h2>\n",
       "\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">But \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Google\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Google is\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">TEST</span>\n",
       "</mark>\n",
       " starting from behind.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "ex = [{\"text\": \"But Google is starting from behind.\",\n",
    "       \"ents\": [{\"start\": 4, \"end\": 10, \"label\": \"ORG\"},\n",
    "                {\"start\": 4, \"end\": 13, \"label\": \"TEST\"}\n",
    "               ],\n",
    "       \"title\": \"Test\"},]\n",
    "#      {\"text\": \"But Google is starting from behind.\",\n",
    "#        \"ents\": [\n",
    "# #                 {\"start\": 4, \"end\": 10, \"label\": \"ORG\"},\n",
    "#                 {\"start\": 4, \"end\": 13, \"label\": \"TEST\"}\n",
    "#                ],\n",
    "#        \"title\": \"Test\"}]\n",
    "html = displacy.render(ex, style=\"ent\", manual=True, options={\"colors\":{}})\n",
    "#                        {\"colors\":{\"ORG\":\"yellow\"}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dddb13b3",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4491f5b2",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "71826e1f",
   "metadata": {},
   "outputs": [],
   "source": [
    "from spacy.tokens import Doc\n",
    "\n",
    "Doc.set_extension('my_ents', default=None, force=True)\n",
    "\n",
    "def move_ents_to_attr(doc):\n",
    "    if doc._.my_ents is None:\n",
    "        doc._.my_ents = []\n",
    "    doc._.my_ents.extend(doc.ents)\n",
    "    doc.ents = []\n",
    "    return doc\n",
    "\n",
    "\n",
    "nlp = spacy.load(\"en_core_web_sm\")\n",
    "nlp.add_pipe(move_ents_to_attr, last=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "461be7e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp = spacy.load(\"en_core_web_sm\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "4dc75800",
   "metadata": {},
   "outputs": [],
   "source": [
    "# text = \"But Google is starting from behind.\"\n",
    "text = \"When Sebastian Thrun started working on self-driving cars at Google in 2007, few people outside of the company took him seriously.\"\n",
    "doc = nlp(text)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "af314068",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "When Sebastian Thrun started working on self-driving cars at Google in 2007, few people outside of the company took him seriously."
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "doc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "1d4403c8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">When \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sebastian Thrun\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " started working on self-driving cars at \n",
       "<mark class=\"entity\" style=\"background: #7aecec; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Google\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">ORG</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #bfe1d9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2007\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DATE</span>\n",
       "</mark>\n",
       ", few people outside of the company took him seriously.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, style=\"ent\", options={\"colors\":{}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "da12e852",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
